


PERFORMANCE. PROVEN EFFECTIVENESS WITHIN A WIDE SAFETY MARGIN.



Month after month. Year after year. The evidence continues to accumulate.

While Roche Laboratories already knows more about the performance of Librium than anyone else, we keep on learning more every day.

For example, the highly favorable benefits-to-risk ratio of Librium is a well-documented matter of record.

It's a record which shows that Librium is seldom associated with serious side effects. That Librium rarely interferes

with mental acuity. That most common side effects are dose-related and therefore — to a large extent — avoidable.

As with all CNS-acting drugs, however, patients should be cautioned against hazardous activities requiring complete mental alertness and against combined effects with alcohol.

Proven performance within a wide safety margin. Basically, that's what Librium is all about:

LIBRIUM® 
chlordiazepoxide HCl/Roche
THE ANXIETY-SPECIFIC

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Relief of anxiety and tension occurring alone or accompanying various disease states.

Contraindications: Patients with known hypersensitivity to the drug.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. As with all CNS-acting drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering to addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of childbearing age requires that its potential benefits be weighed against its possible hazards.


Precautions: In the elderly and debilitated, and in chil-

dren over six, limit to smallest effective dosage (initially 10 mg or less per day) to preclude ataxia or oversedation, increasing gradually as needed and tolerated. Not recommended in children under six. Though generally not recommended, if combination therapy with other psychotropics seems indicated, carefully consider individual pharmacologic effects, particularly in use of potentiating drugs such as MAO inhibitors and phenothiazines. Observe usual precautions in presence of impaired renal or hepatic function. Paradoxical reactions (e.g., excitement, stimulation and acute rage) have been reported in psychiatric patients and hyperactive aggressive children. Employ usual precautions in treatment of anxiety states with evidence of impending depression; suicidal tendencies may be present and protective measures necessary. Variable effects on blood coagulation have been reported very rarely in patients receiving the drug and oral anticoagulants; causal relationship has not been established clinically.

Adverse Reactions: Drowsiness, ataxia and confusion may occur, especially in the elderly and debilitated.

These are reversible in most instances by proper dosage adjustment, but are also occasionally observed at the lower dosage ranges. In a few instances syncope has been reported. Also encountered are isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, increased and decreased libido—all infrequent and generally controlled with dosage reduction; changes in EEG patterns (low-voltage fast activity) may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have been reported occasionally, making periodic blood counts and liver function tests advisable during protracted therapy.

Supplied: Librium® Capsules containing 5 mg, 10 mg or 25 mg chlordiazepoxide HCl. Librium® Tablets containing 5 mg, 10 mg or 25 mg chlordiazepoxide.

 Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

Medical Tribune

© 1976, Medical Tribune, Inc.

and Medical News

Vol. 17, No. 25

world news of medicine and its practice—fast, accurate, complete

Wednesday, August 4, 1976

Exclusive Interview:

Dr. Cooper Defends Swine-Type Flu Shots

'We Had No Choice... but to Take the Action We Did,' Says NEW Official

Medical Tribune Report

WASHINGTON—In an exclusive interview amid rising debate on the crash program to immunize over 200 million Americans against swine-type influenza, Dr. Theodore Cooper, Assistant Secretary for Health, Department of Health, Education and Welfare, stressed that the government's vaccination decision was an essential and responsible one based on fundamental scientific judgments in the absence of test data.

"We had no choice as public officials but to take the action we did to protect the public health, even though we do

See Editorials on Page 11

not know for sure there will actually be an epidemic of influenza this fall or winter," Dr. Cooper said.

Besides the validity of mounting such a program, areas covered in the interview by Dr. Arthur M. Sackler, International Publisher of Medical Tribune, included: Why the vaccine was not stockpiled and other options utilized; why the government does not embark on crash programs for other "epidemic" diseases such as cardiovascular disease, and the differences in handling the vaccine program and

Continued on page 22



DR. COOPER

Dr. Sackler Questions Gov't Procedures: Text of Interview: Part I

It seems to me that the decision for our national effort to head off a swine flu epidemic is based not on hard data but rather on scientific judgment. Is that true?

You are right as rain about the decisions involved in this program. They are based on medical and scientific judgments. Frequently I am asked if the swine flu program sets a precedent for similar actions against other influenza viruses or other diseases in the future. I reply that these will have to be judged on their own merits just as this issue was decided by the best public health and scientific expertise we could bring to bear.

Continued on page 23

Tumor-Specific Antigen Aids Recovery from Lung Cancer

By KRISTIN WHITE
Special Tribune Correspondent

NEW YORK — Mobilizing the immune system to eliminate any lung cancer cells lingering after surgery and adjuvant chemotherapy offers dramatic therapeutic promise, according to Drs. Thomas H. M. Stewart and Jules E. Harris, of the University of Ottawa, and Ariel C. Hollinshead, Ph.D., Pro-

fessor of Medicine at George Washington University Medical Center in Washington, D.C.

Dr. Hollinshead was recently elected Medical Woman of the Year "in recognition of her pioneer work in separating tumor-related antigens from the cell surface, and in showing the reactivity of purified antigens for specific types

Continued on page 8

Immunologic Link?

Progesterone Seen Preventing Fetal Rejection

By NATHAN HORWITZ
Medical Tribune Staff

SAN FRANCISCO—Evidence that progesterone may be a vital link in preventing immunologic rejection of the fetus by the mother was reported here by a team at the University of California San Francisco.

Studies showing that the hormone exerts a powerful local immunosuppressive effect within the placenta, thereby protecting the fetus against rejection, were described by Penati K. Sileri, Ph.D., who said the findings could have far-ranging implications in transplantation surgery and in the treatment of spontaneous abortion.

Speaking at the meeting of the Endocrine Society, Dr. Sileri, who is Professor of Obstetrics-Gynecology at UCSF, said the team's animal experiments and in vitro studies of human cell cultures have provided the first evidence for the long-held but never confirmed hypothesis that progesterone may exert the same immunosuppressive in utero effect as that of cortisol or glucocorticoids in transplantation management.

An important observation to emerge from the studies, Dr. Sileri reported, is

Continued on page 6

Healing of Hip Joint May Avoid Surgery in Juvenile Arthritis



10/75
A 12-year-old girl, age 12, with systemic JRA for nine years, shows narrowing of joint spaces and subchondral cysts of acetabulum and femoral heads. After three years' therapy, following intensive physical therapy and salicylates, indometh-



acin, and other anti-arthritis drugs, x-ray (right) shows widening of joint spaces and sharp cortical margins of the acetabulum and femoral heads. Before treatment, girl relied on crutches to walk; three years later she could ride a bicycle. See page 3.

Scottish & Newcastle
Sulston Gb Ltd
Suton Healthcare Gr
Sheaffer Pen (UK) Lt
Smith & Nephew
SmithKline Beecham
Somerville Stores
Sony United Kingdom
St Ivel Ltd
Stratford-Upon-Avon
Tate & Lyle Sugars
Taunton Cider plc
Telford Foods Ltd
Tesco Stores Ltd

"packaging
other exhi
opportuni
to meet
not avail
chance t
discussi
new ide
Kevin Hy
Walla Gra

The Boots
The Choes
The inven
The Kery
The New
The Well
The Well
Thornton
Thomson
Tomy U
Tovall I
Trafford
Tranfle
Treals
Tulip
Vitam
W A
W Jo
Well
Wes
Whi
Whi
W

Purchasing

Purchasing
Management
Buyer
Manager
Supply Chain Manager
Director

Pharmaceuticals Ltd
Mortlake Road

Current Opinion

Double-Blind and Clinical Observation

by CHARLES HARRIS, M.D., F.A.C.P.
Toms River, N.J.

THE TERM, DOUBLE BLIND, has become to scientific jargon what "In God We Trust" once meant to numismatists. What has happened to our coinage is obvious and similarly some vaunted double blind studies may also turn out to be amalgams of fact and fancy.

Statistics is a delicate mathematical technique devised to estimate the truth of a universal sample. If indeed 70% of Americans had brown eyes, this fact could be estimated by determining eye color of smaller samples. If in choosing samples, one hundred individuals were counted in which 70% had blue eyes, statistical computation will tell you what the odds are of choosing 70 blue eyed individuals from a population in which 70% had brown eyes. By convention, if the odds of making this choice were less than 5% when choosing by chance alone, then the probability exists that some blond blue eyed foreigners were smuggled into the sample, or the sample represented a long-shot choice.

The Null Hypothesis

The null hypothesis states that there is no difference between the groups of data being examined. If the data are so disparate between groups that the odds of their being chosen from the same group is 5% or less, then statisticians might consider that the null hypothesis has been rejected, and that the two groups represent different populations. On the other hand, if the groups differ, but there is a 10% possibility that the difference could be accounted for by chance alone, then the null hypothesis is accepted, and the groups of data represent the same population.

This is an imposing tool without which much research would crawl at a snail's pace. As a matter of fact, without calculators and computers, statistics would crawl at a snail's pace, because the computations are becoming too cumbersome to perform by hand in a reasonable period of time.

From Single to Double Blind

The concept of double blind became popular with studies of drug efficacy. The medication to be tested was usually assigned to a physician at a center from which a more or less uniform population would be drawn—a nursing home, a prison, a university, the armed services. If, for instance, a sleeping tablet were being tested, half the group would get the sleeping tablet, the other half would receive a placebo. One was taken to dress the sleeping tablet and placebo in the same jackets so that the subject would be fooled. This was the single blind study. A scoring system was then set up to determine the quality of sleep enjoyed by each group and the scores compared statistically.

It soon became apparent that if the doctors knew which patient received the real and which the spurious drug, as scoreskeepers they might be biased. In designating the scores. As a result, the double-blind study was born in which not only the patients, but the doctors were kept in ignorance of which capsule contained the real thing.

The technique of the double-blind study is ingenious and useful, but those qualities do not require that double-blind studies be blindly accepted.

What Statistics Do

Statistics are useful in making educated guesses about the meaning of contemporary events and useful in formulating projections. They hover about the truth like a boat on a mooring, without ever actually touching it.

About Dr. Harris:

Dr. Charles Harris, whose training earned certification in pathology and eligibility in medicine, has spent two decades in cancer research: the first at a university research institute; the second at a geriatric institution where he bartered service to the department of medicine for the use of their research laboratories. Prior to going into private practice, he served briefly as medical director for a community health center. His book, *One Man's Medicine* (Harper & Row, 1975), is a literary paraphrase of these experiences.

Another estimate of the truth, of course, is experience. If, for example, the majority of the population zeros in on a certain sleeping potion and

In his book, Dr. Harris concludes that it is in private practice that the physician can best serve his patient. After experience on both sides of the institutional fence, Dr. Harris feels that the physician must marshal the facilities of the medical apparatus on behalf of his patients, rather than be an agent of institutions in the care of patients. He cites two reasons to support this view: first, responsibility and authority cannot be divided; secondly, neither institutions nor governments are licensed to practice medicine: physicians are—Editor.

"swears by it," the odds are that the medication is probably effective and for the near term relatively harmless. If something as dramatic as penicillin

Lasix Tablets (furosemide) 20 mg and 40 mg in hypertension.

Lasix Tablets have been shown to reduce elevated blood pressure in diuretic-responsive patients.

Lasix. For the treatment of essential benign hypertension.

appears on the horizon, no double-blind experiments are necessary to prove its efficacy.

What Is Not Obvious

Statistics are useful in orienting us to that which is not obvious. They do not necessarily prove the point, but raise a warning flag that suggests more careful observation of a possible side effect. They warn the physician to be on the lookout. Certainly, if the undesirable side effects of a drug were readily apparent, the practicing physicians would have detected them in the normal course of practice. Once alerted by statistical studies that less obvious side effects might indeed occur, the physician is guided to make a choice between the benefit of the drugs and the potential risk of administering them. Traditionally, physicians have

been trained to choose between the risk and benefit of any drug they administer, and the populace, which is not an ass, has been willing to accept this choice. Too often, however, double-blind studies that have imagined certain therapies have never measured the deleterious effects of alternative therapies.

Another factor often ignored by statistics is the sense of well-being of the patient receiving a medication. The question, "How are you feeling?" is a total statistical survey of one patient, and the answer, "Much better," is significant to the nth degree. After all, you can't go into a room full of caged rats and ask, "How are you, fellas?" and expect to get statistically useful information. Thus, the audience to whom a statistic is presented plays a vital role in the usefulness of the statistic.

Hardly a day goes by without erudite prose erupting to show that doctors just do not know what they are doing. The most recent expose was a five-day series in the *New York Times* which used statistics freely to batter an already beleaguered medical profession. When the *Times* presented its recent survey about the damage doctors do, it buttressed its insinuations with reams of supposed statistical studies. Many statements that in the aggregate constituted an unwarranted attack on the practicing physician are prefaced with the devastating stopper "... in a double-blind study..." For the doctor, the "statistics" presented by the *Times* simply raised questions which required careful study or corroboration. To the layman, the articles were a disservice that caused a minor panic. The physician is able to evaluate the material in

the light of his personal experience and that of his colleagues; he is able to measure the greater good against the lesser risk. The patient, on the other hand, sees it as an all or none proposition, and wonders whether he is being poisoned.

The science of statistics is great. It is cross-sectional, informative, ingenious, and instantaneous. But it is not necessarily the truth, nor more valid for the individual, than the data accrued over the years by experienced and observant physicians and patients alike who seek to trade the greater good for the calculated risk.

The Absurd Reduction

Recent articles simplistically implying that doctors do more harm than good pose the null hypothesis that there is no difference between doctors and other people with respect to effective practices of medicine, that the profession of medicine is superfluous. If so, the conclusion is an absurd reduction of the medical experience, and an equally absurd reflection of the times we live in and the *Times* we read.

Whom the Gods would destroy, they first make mad; whom governments and the press would destroy, they first malign.

Fibrinogen Assay Aids Detection of 90% Bladder Ca

Medical Tribune Report

BUFFALO—Researchers at Roswell Park Memorial Institute here have achieved a 90% bladder cancer detection rate by supplementing the conventional cytology detection method (which scores only about 70%) with a test for the presence of fibrinogen degradation products (FDPs) not normally present in the urine.

In patients with active bladder cancer, cytology-FDP testing correctly detected the disease in 18 of 20 patients, Dr. Zew Wasjman, a urologist, told MEDICAL TRIBUNE. There were negative results in 46 others with inactive bladder cancer and in 20 controls who neither had a history of bladder cancer nor any other evidence of cancer, Dr. Wasjman said.

Inexpensive Screening

The cytology-FDP tests are inexpensive and could be used in screening programs after further testing on control groups is completed in about a year, he said. The new detection method could have important applications among workers in rubber, chemical, and synthetic dye industries who are already being screened by conventional means because their exposure to aromatic amines means they run a higher risk of bladder cancer.

Exposure to amines and cigarette smoking is partially responsible, most experts agree, for the doubling of the incidence of bladder cancer in the last 10 years. The American Cancer Society estimates that it will claim the lives of 6,600 men and 2,900 women in 1976.

Co-investigators with Dr. Wasjman were Drs. T. Ming Chu, Claude E. Merrin, and Gerald P. Murphy.

Lasix Tablets (furosemide) 20mg and 40mg in hypertension.

A brief summary of the Prescribing Information for

Lasix® (furosemide) Tablets 20 mg and 40 mg

WARNING:—Lasix (furosemide) is a potent diuretic which if given in excessive amounts can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dose schedule have to be adjusted to the individual patient's needs. (See under "Dosage and Administration.")

Indications:—Lasix (furosemide) is indicated for the treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.

Hypertension:—Lasix (furosemide) may be used for the treatment of hypertension alone or in combination with other antihypertensive drugs. Hypertensive patients who cannot be adequately controlled with thiazides may possibly not be adequately controlled with Lasix (furosemide) alone.

CONTRAINDICATIONS:—Because animal reproductive studies have shown that Lasix (furosemide) may cause fetal abnormalities, the drug is contraindicated in women of childbearing potential. (See "Additional Information.")

Lasix (furosemide) is contraindicated in anuria. If anuric patients and oliguria occur during a treatment of severe congestive heart failure, the drug should be discontinued. In hepatic cirrhosis and in cases of hepatic encephalopathy, therapy should not be initiated until the basic condition is improved or corrected. Lasix (furosemide) is contraindicated in patients with a history of hypersensitivity to this compound.

Warnings:—In severe cases of anuria may result in dehydration and reduction in blood volume, with circulatory collapse and with the possibility of vascular thrombosis and embolism, particularly in elderly patients. Therefore, blood counts should be obtained frequently during therapy. Patients should be advised to avoid excessive heat and to avoid prolonged exposure to sunlight. Patients should also be advised to avoid prolonged exposure to sunlight.

Precautions:—In patients with hepatic cirrhosis and ascites, initiation of therapy with Lasix (furosemide) is best carried out in the hospital. Sudden alteration of fluid and electrolyte balance can precipitate hepatic coma, therefore, close observation is necessary during the period of a diuresis. Supplemental potassium chloride and, if required, an anesthetic agent are helpful in preventing hypokalemia and metabolic alkalosis.

Patients should be observed regularly for the possible occurrence of blood dyscrasias, liver damage, or other idiosyncratic reactions.

In those instances where potassium supplementation is required, an oral liquid preparation should be used rather than an injected solution. There have been several reports, published and unpublished, concerning non-specific small bowel lesions consisting of stenosis, with or without ulceration, associated with the administration of Lasix (furosemide) tablets with potassium salts. These lesions may occur with or without ulceration, and should be suspected if there is abdominal pain, distention, nausea, vomiting, or obstructive intestinal bleeding occurs.

Patients with known or suspected sensitivity may show allergic reactions to Lasix (furosemide).

Precautions:—As with any potent diuretic, excessive dehydration may occur during therapy with Lasix (furosemide), especially in patients receiving higher doses and a restricted salt intake. Electrolyte depletion may be reflected by weakness, dizziness, fatigue, leg cramps, anorexia, vomiting, and in mental status.

Precautions:—Hypokalemia can occur and may be reflected by weakness, dizziness, fatigue, leg cramps, anorexia, vomiting, and in mental status.

When parenteral use of Lasix (furosemide) is indicated, it should be kept in mind that cases of renal and reversible hearing impairment have been reported. These have also been some reports of cases in which reversible hearing impairment occurred. Usually, hearing has been reported when Lasix (furosemide) was injected rapidly in patients with severe impairment of renal function or doses exceeding several times the usual recommended dose and in whom other drugs known to be ototoxic were given at the same time. In some cases, the hearing impairment was reversible. In other cases, it was not. In some cases, the hearing impairment was reversible. In other cases, it was not.

Lasix (furosemide) should be used with caution in patients with renal insufficiency. The effects of Lasix (furosemide) on patients with renal insufficiency have been studied. The results of these studies indicate that the drug is effective in patients with renal insufficiency. The results of these studies indicate that the drug is effective in patients with renal insufficiency.

Patients receiving high doses of Lasix (furosemide) in conjunction with Lasix (furosemide) may experience hypokalemia at lower doses because of competitive inhibition of potassium reabsorption.

Lasix (furosemide) may potentiate the hypokalemia of captopril. Therefore, Lasix (furosemide) and captopril should not be administered simultaneously.

Lasix (furosemide) should be used with caution in patients with renal insufficiency.

exercise in administering Lasix (furosemide) to patients undergoing therapy with Lasix (furosemide), and it is advisable to discontinue Lasix (furosemide) for one week prior to any elective surgery.

Adverse Reactions:—Various forms of dermatitis, including urticaria and rare forms of exfoliative dermatitis, erythema multiforme, purpura, paronychia, blurring of vision, postural hypotension, rashes, vomiting, or diarrhea.

Anemia, leukopenia, aplastic anemia, and thrombocytopenia (with purpura). Rare cases of agranulocytosis which responded to treatment.

In addition, the following rare adverse reactions have been reported, however, causality to the drug has not been established with certainty: sweet taste, oral and gastric burning, paronychia, headache, jaundice, thrombophlebitis and emboli, and acute pancreatitis.

Lasix (furosemide)-induced diuresis may be accompanied by weakness, fatigue, light-headedness or dizziness, muscle cramps, thirst, increased perspiration, urinary bladder spasm, and symptoms of urinary frequency.

Dosage and Administration
ADULTS
The usual adult dose of Lasix (furosemide) is 20 to 80 mg given as a single dose.

If the diuretic response with a single dose of 20 to 80 mg is not satisfactory, the following schedule should be used: increase the dose to 40 or 80 mg and repeat the dose in 6 to 8 hours after the previous dose until the desired diuretic effect has been obtained. This individualized dose should then be given once or twice daily. The dose of Lasix (furosemide) may be cautiously titrated up to 600 mg per day in those patients with severe clinical edema.

With doses exceeding 60 mg daily and given for prolonged periods, careful clinical and laboratory observations are particularly advisable.

Hypertension:—The usual dose of Lasix (furosemide) is 40 mg twice daily both for treatment of therapy and for maintenance. Careful observations for changes in blood pressure must be made when this compound is used with other antihypertensive drugs, especially during initial therapy. The dosage of other agents must be reduced if necessary.

For maintenance therapy in infants and children, the dose should be adjusted to the minimum effective level.

How Supplied:—Lasix Tablets 40 mg (furosemide) supplied as white, round, monogrammed, scored tablets.

Lasix Tablets 20 mg (furosemide) supplied as white, oval, monogrammed tablets.

Warnings:—Deposits in dark containers. Exposure to light may cause slight discoloration which, however, does not affect potency.

Additional Information
Toxicology
The acute toxicity of Lasix (furosemide) has been determined in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats, and dogs. In all three animal species, the LD₅₀ of Lasix (furosemide) exceeded 1000 mg/kg of body weight, while the intravenous LD₅₀ ranged from 300 to 600 mg/kg.

The acute toxicity of Lasix (furosemide) was characterized by hypokalemia, hypotension, and collapse. Surviving animals often became anuric and died of electrolyte depletion.

Chronic toxicity studies with Lasix (furosemide) have been conducted in mice, rats,

Tumor-Specific Antigen Aids Recovery from Lung Cancer

Continued from page 1

of cancer with important implications for immunodiagnosis and immunotherapy."

The clinicians report that of 26 lung cancer patients treated post-surgically with immunotherapy or immunotherapy plus chemotherapy all are alive and 24 are disease-free, half of them for more than 21 months. Among a control group of 23 patients treated by standard means, six have died.

The new factor in the treatment strategy is an allogeneic, tumor-specific antigen, developed and prepared by Dr. Hollinshead in Washington and used clinically by Dr. Stewart in Ottawa. Despite the modest number of patients and the preliminary nature of the study, the investigators are cautiously hopeful that their work will lead to a better prognosis for lung cancer patients, 40-50% of whom now die from recurrent disease within two years after surgery, they told MEDICAL TRIBUNE in an interview.

Beginning of New Era

Dr. Stewart and Dr. Hollinshead, who have been collaborating in the project since 1969, see their achievement as the beginning of a new era in the treatment of all types of tumors. "We admit that this is a very small series, but we do feel that the preliminary results suggest the immunotherapy approach might well be applicable to other tumor systems," Dr. Stewart said.

After surgery, Drs. Stewart and Harris treated each patient who received immunotherapy with methotrexate, then "rescued" the patient from the toxicity of the massive dose of MTX with citrovorum factor. The procedure is repeated 30 days and 60 days later. Seven to nine days after each course of MTX and citrovorum factor, the patient receives an IM injection of tumor antigen, derived from tumor cells of the same histologic type as his own combined with Freund's complete adjuvant. Each of the three doses contains between .521 mg and 1 mg of antigen, depending on the patient and the availability of antigen, for a total of about 1.5 mg.

Dr. Stewart believes that the chemotherapy and immunization enhance each other's effectiveness, and plotted his clinical strategy to make the most of this synergistic interaction.

'Rebound Overshoot'

Methotrexate suppresses the ability of the bone marrow to produce lymphocytes. "After rescue with citrovorum factor, however, the immune system not only recovers, it comes back even stronger than before," said Dr. Harris, who calls the phenomenon "rebound overshoot." At this point, the tumor antigen is given in order to equip the new army of lymphocytes, recruited by the methotrexate, with weapons specifically lethal to tumor cells.

The patients tolerated the vaccine well, although all of them developed ulcers at the vaccination site, most of which became infected. Staphylococcus

aureus caused most of the infections, which responded well to antibiotics and healed completely within 12 months. In seven patients, high fever (up to 40° C) followed the second injection of the vaccine. The fever lasted less than 30 hours and required no treatment beyond bed rest and aspirin.

The investigators emphasized that their work, which they presented at the recent meeting of the American Society of Clinical Oncologists in Toronto, is still experimental and cannot at present be applied to large numbers of patients. The sheer logistics involved complicate the picture further.

Continued in the next issue




In her lab at George Washington University Medical Center, Ariel C. Hollinshead, Ph.D., elected "Medical Woman of the Year" for her "pioneer work," adjusts microconcentrators during final purification of lung cancer vaccine.

The ultimate objective test: sleep laboratory proof of effectiveness... now in geriatric insomnia patients

Six female insomniacs, ranging in age from 67 to 82 years, received Dalmane (flurazepam HCl) for seven consecutive nights in the sleep research laboratory. Improvement over pre-treatment baseline levels was significant for sleep induction and sleep maintenance ($p < .05$). And the greater the sleep problem in these patients, the better the effect with Dalmane (significant correlation at $p < .01$ level).



Elderly insomniacs fall asleep faster, sleep longer!



Results expand and confirm objective proof of efficacy in younger adults with insomnia

The effectiveness of Dalmane (flurazepam HCl) was demonstrated in earlier studies of younger adults with trouble falling asleep, staying asleep or waking long enough. On average, these studies, Dalmane induced sleep within 17 minutes and prolonged 7 to 8 hours of sleep, at the same time reducing number of nighttime awakenings.

Relative safety, even in patients on warfarin

Morning "hang-over" has been rarely infrequent with Dalmane. And no unacceptable increase in prothrombin time has been reported in warfarin patients on Dalmane. The usual dose is 30 mg HCl; in elderly and debilitated patients, initial dose to 15 mg to preclude oversedation, dizziness or ataxia.

pathology. A systematic exploration of the liver and bile ducts in patients with these symptoms reveals no anomaly, even with the most sensitive tests. And patients suffering from real illness of the liver, associated with a major deterioration of hepatic functions, such as chronic hepatitis or certain cirrhoses, never complain of these symptoms so widely attributed to the liver.

In many cases the precise cause of the patient's "liver ailment" may be detected. Migraine headaches, for example, are related to a vasomotor phenomenon, not the liver, and they may be associated with vomiting, frequently the primary symptom. Their treatment, particularly with ergotamine derivatives, is often very effective—but this has nothing to do with the liver.

Right subcostal pains may be related to many different causes, such as chole-

lithiasis, duodenal ulcer, or colic. Similarly, intolerance to certain foods is often accompanied by digestive reactions, such as nausea, vomiting, diarrhea—the origin of which is gastric and intestinal, not hepatic.

It may happen that the origin of the symptoms remains unknown, said the French hepatologists, but there is too much haste on the part of patients and physicians to blame the liver without proof. The abuse of medications is often habitual in such patients, leading to iatrogenic pathology. Cessation of drug taking alone may lead to a spectacular regression of the "liver attack" in a substantial number of cases.

The "liver attack," said Prof. Dhumeaux, is a convenient diagnosis, with which the patient is readily satisfied even though the real cause of the symptoms may then be ignored.

Before prescribing Dalmane (flurazepam HCl), please consult complete product information, a summary of which follows:

Indications: Effective in all types of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakening; in patients with recurring insomnia or poor sleeping habits; and in acute or chronic medical situations requiring restful sleep. Since insomnia is often transient and intermittent, prolonged administration is generally not necessary or recommended.

Contraindications: Known hypersensitivity to flurazepam HCl.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. Caution against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Use in women who are or may become pregnant only when potential benefits have been weighed against possible hazards. Not recommended for use in persons under 15 years of age. Though physical and psychological dependence have not been reported on recommended doses, use caution in administering to addiction-prone individuals or those who might increase dosage.

Precautions: In elderly and debilitated, initial dosage should be limited to 15 mg to preclude oversedation, dizziness and/or ataxia. If combined with other drugs having hypnotic or CNS depressant effects, consider potential additive effects. Empty usual precautions in patients who are severely depressed, or with latent depression or suicidal tendencies. Periodic blood counts and liver and kidney function tests are advised during repeated therapy. Observe usual precautions in presence of impaired renal or hepatic function. Adverse Reactions: Dizziness, drowsiness, lightheadedness, staggering, ataxia and

falling have occurred, particularly in elderly or debilitated patients. Severe sedation, lethargy, disorientation and coma, probably indicative of drug intolerance or overdose, have been reported. Also reported were headache, heartburn, upset stomach, nausea, vomiting, diarrhea, constipation, GI pain, nervousness, talkativeness, apprehension, irritability, weakness, palpitations, chest pains, body and joint pains and GU complaints. There have also been rare occurrences of leukopenia, granulocytopenia, sweating, flushes, difficulty in focusing, blurred vision, burning eyes, faintness, hypotension, shortness of breath, pruritus, skin rash, dry mouth, bitter taste, excessive salivation, anorexia, euphoria, depression, slurred speech, confusion, restlessness, hallucinations, and elevated SGOT, SGPT, total and direct bilirubins and alkaline phosphatase. Paradoxical reactions, e.g., excitement, stimulation and hyperactivity, have also been reported in rare instances.

Dosage: Individualize for maximum beneficial effect. Adults: 30 mg usual dosage; 15 mg may suffice in some patients. Elderly or debilitated patients: 15 mg initially until response is determined. Supplied: Capsules containing 15 mg or 30 mg flurazepam HCl.

REFERENCES:

1. Frost JJ Jr: Data on file, Medical Department, Hoffmann-La Roche Inc., Nutley NJ
2. Data on file, Medical Department, Hoffmann-La Roche Inc., Nutley NJ
3. Robinson DS, Anklon EL: Interaction of benzodiazepines with warfarin in man, in *The Benzodiazepines*, edited by Garattini S, Mussini E, Randall LO, New York, Raven Press, 1973, p. 641

New evidence proves insomnia relief in elderly patients

Dalmane®
(flurazepam HCl) ©

One 15-mg capsule h.s.—initial dosage for elderly or debilitated patients.
One 30-mg capsule h.s.—usual adult dosage (15 mg may suffice in some patients).

For all common types of insomnia:

ROCHE LABORATORIES
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

from Britain

MDs Advised to Look for Scurvy In 'Gout' Patients

Continued from page 2

treatment, it is arguable as to what extent maintaining normal uric acid levels will help renal function.

In the case of asymptomatic hyperuricaemia, now more commonly seen since the advent of autoanalyses, his advice is not to rush into treatment.

With serum uric acid levels of 8-8.9 mg per 100 ml, only about 25% of men turn out to have gout. This proportion jumps to 90% with serum uric acid levels of more than 9.0 mg %.

The risks to be considered when faced with a patient with asymptomatic hyperuricaemia are gout (which is nothing to worry about till the first symptoms appear), renal damage, and ischaemic heart disease.

Little is known about the likelihood of an asymptomatic hyperuricaemic patient developing either renal impairment or ischaemic heart disease.

A mild renal impairment is common in gout patients but it is a case of which is the cart and which the horse. There is, of course, the possibility of uric acid stones, Dr. Scott concluded.

from Japan

Protection Urged For Fingertips of Isotope Workers

Continued from page 2

for 13 weeks without protection, thereby exceeding the maximum digital exposure tolerance dose of 20 rems.

More recently, a questionnaire circulated among some members—those over 40 years of age—of the Society of Medicoradiation and the Society of Clinical Radiation Technicians disclosed smooth finger tips, and other anomalies in 24% of the physician group and 17% of the technicians. A follow-up study of fingerprints in 102 responding physicians showed 3.9% to have a greater number of wrinkles and shallower furrows than normal fingerprints (see photo).

In radiologic practice, acute disorders due to exposure rarely occur, Dr. Koga said. The commonly encountered disorders seem to be those that develop more slowly: cutaneous atrophy, leukemia, cancer, cataracts, premature aging, and shortened life expectancy.

Back in 1970, it was estimated that only about 0.3% of medical, paramedical and dental personnel in Japan were occupationally exposed to more than 5 rads, Dr. Koga said. Although this figure has remained more or less unchanged over the intervening years, there is some evidence that the actual exposure level may be higher.

Dr. Koga concluded that hands and fingertips may be especially vulnerable to possible radiation hazards, particularly with the increasing clinical use of isotopes, such as 99mTc, which have a short half-life period.

Scottish & Newcastle
Sollatop GB Ltd
Sutton Healthcare Corp
Shenley Pen (UK) Ltd
Smith & Nephew
SmithKline Beecham
Somerfield Stores
Sony United Kingdom
St Ivel Ltd
Stratford-Upon-Avon
Tate & Lyle Sugars
Taunton Cider plc
Telford Foods Ltd
Tesco Stores Ltd

"packaging"
other exhibi
opportunit
to meet
not availa
chance to
discussio
new ideas
Kevin Hyde
Wella Group

The Boots
The Chester
The Inver
The Korr
The New
The Ryth
The Well
The Well
Thomson
Thomson
Tomy Ltd
Tovall
Tranite
Trants
Trebor
Tullip
Vitam
W A
W J
W J
W J
W J
W J
W J

gar

gar


Purchasing

Purchasing
Department Manager
ing Buyer
anager
Manager
Supply Chain Manager
er
ons Director

by
ants Ltd
e
er Mortlake Road

Are all antianxiety- anticholinergic therapies the same?

Not if you know Librax®.



Only Librax provides

■ the well-known antianxiety action
of Librium® (chlordiazepoxide HCl)

plus

■ the prompt antisecretory-
antispasmodic action
of Quarzan® (clidinium Br)

with the convenience and economy
of a single medication...
all advantages in sustaining
patient compliance

adjunctive
dual-action

Librax®

Each capsule contains 5 mg chlordiazepoxide HCl
and 2.5 mg clidinium Br.

For relief of psychovisceral
symptoms in irritable bowel
syndrome* and duodenal ulcer*

A distinctive antianxiety-anticholinergic agent

Please consult complete prescribing information, a summary
of which follows:

Indications: Based on a review of this drug by the
National Academy of Sciences—National Research Council
and/or other information, FDA has classified the indications
as follows:

"Possibly" effective as adjunctive therapy in the treat-
ment of peptic ulcer and in the treatment of the irritable
bowel syndrome (irritable colon, spastic colon, mucous
colitis) and acute enterocolitis.

Final classification of the less-than-effective indications
requires further investigation.

Contraindications: Patients with glaucoma, prostatic hyper-
trophy and benign bladder neck obstruction, known hypersen-
sitivity to chlordiazepoxide hydrochloride and/or clidinium
bromide.

Warnings: Caution patients about possible combined effects
with alcohol and other CNS depressants. As with all CNS-acting
drugs, caution patients against hazardous occupations requiring
complete mental alertness (e.g., operating machinery, driving).
Though physical and psychological dependence have rarely
been reported on recommended doses, use caution in adminis-
tering Librium® (chlordiazepoxide hydrochloride) to known

addiction-prone individuals or those who might increase dosage;
withdrawal symptoms (including convulsions), following discon-
tinuation of the drug and similar to those seen with barbiturates,
have been reported. Use of any drug in pregnancy, lactation, or
in women of childbearing age requires that its potential benefits
be weighed against its possible hazards. As with all anticholiner-
gic drugs, an inhibiting effect on lactation may occur.

Precautions: In elderly and debilitated, limit dosage to small-
est effective amount to preclude development of ataxia, over-
sedation or confusion (not more than two capsules per day initially;
increase gradually as needed and tolerated). Though generally
not recommended, if combination therapy with other psycho-
tropics seems indicated, carefully consider pharmacologic effects
of agents, particularly potentiating drugs such as MAO inhibitors
and phenothiazines. Observe usual precautions in presence of
impaired renal or hepatic function. Paradoxical reactions (e.g.,
excitement, stimulation and acute rage) have been reported in
psychiatric patients. Employ usual precautions in treatment of
anxiety states with evidence of impending depression; suicidal
tendencies may be present and protective measures necessary.
Variable effects on blood coagulation have been reported very
rarely in patients receiving the drug and oral anticoagulants;
causal relationship has not been established clinically.

Adverse Reactions: No side effects or manifestations not
seen with either compound alone have been reported with

Librax. When chlordiazepoxide hydrochloride is used alone,
drowsiness, ataxia and confusion may occur, especially in the
elderly and debilitated. These are avoidable in most instances by
proper dosage adjustment, but are also occasionally observed at
the lower dosage ranges. In a few instances syncope has been
reported. Also encountered are isolated instances of skin eruptions,
edema, minor menstrual irregularities, nausea and decreased
libido—all infrequent and generally controlled with dosage re-
duction; changes in EEG patterns (low-voltage fast activity) may
appear during and after treatment; blood dyscrasias (including
agranulocytosis), jaundice and hepatic dysfunction have been
reported occasionally with chlordiazepoxide hydrochloride, mak-
ing periodic blood counts and liver function tests advisable dur-
ing prolonged therapy. Adverse effects reported with Librax are
typical of anticholinergic agents, i.e., dryness of the mouth, blur-
ring of vision, urinary hesitancy and constipation. Constipation
has occurred most often when Librax therapy is combined with
other spasmolytics and/or low residue diets.



Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

Wednesday, August 4, 1976

MEDICAL TRIBUNE

11

The Only Independent Weekly Medical Newspaper in the U.S.

Medical Tribune

and Medical News
Published by Medical Tribune, Inc.

Action on the Potential Swine Flu Epidemic...

THE THREAT of swine influenza has precipitated action by the President of the United States, HEW and its advisory bodies, and by Congress. "Swine flu" poses problems of hard decisions mandatory for those responsible for the national health. Beyond the mechanics of logistics, it raises legal as well as ethical and medical issues. It demonstrates the extent to which judgments are absolutely essential in the fight against disease. It has also provided, we believe, an exemplar par excellence of double or multiple standards as they exist in government actions on health. All this is the consequence of one death, that of an 18-year-old recruit at Fort Dix.

Let us agree that for "government" to have done nothing in respect to a flu epidemic threat would have been irresponsible and reckless. But let us also compare from a total public health perspective the manner in which the program to combat a potential epidemic has been carried out and the contrast it presents to the endless delays and rigidities imposed by the FDA in respect to new therapeutic agents—of even greater importance.

A case in point is the very real, existing "epidemic" of hypertension to which 25 million Americans are exposed—year in and year out—to the crippling morbidity of strokes and the high mortality of cardiovascular damage. Despite an impressive weight of medical opinion, for many years the FDA has held back approval of effective new drugs on the grounds that its actions would breach the very regulations which, as we note here, seem to have been "thrown to the winds."

Accepting as a premise the government decision to vaccinate 200 million Americans as valid and that everyone has acted in good faith, let us examine all the implications that follow:

1. What hard experimental and clinical data was available on the acute and chronic toxicity of the specific "swine flu" vaccine which virtually all Americans are supposed to receive?
2. Some viruses are related to cancer and teratogenicity. Have carcinogenicity and teratogenicity studies similar to those required for drugs been carried out?
3. What about reports that prisoners will participate in the screening program? How does this comport with recent complaints that such volunteers should not participate in drug research?
4. Will true "full disclosure" truly inform the general public both as to the chances of the epidemic occurring, the

extent of its dangers, or the efficacy of the vaccine and its potential side-effects?

5. What is the morality of vaccinating every person in a population to prevent a pandemic whose potential threat would be primarily to the elderly and high risk groups?

6. What about the "long-term follow-up" currently under consideration for other experimental medications? In view of the scope and the unanswered questions indicated above, what plans have been made for such monitoring of this unique national experiment?

Let us be absolutely clear. We do not believe that the issues we raise rule out the necessity for responsible government action to head off a swine flu epidemic. Some of us would have preferred to see the swine flu vaccine prepared so as to be available, plans made to inoculate high risk groups and then a reserve program to extend protection depending on developing circumstances. We do not, despite such differences in opinion, fault either the President, the Assistant Secretary for Health, or Congress. We believe that all, including HEW, the White House Office of Management and Budget, the Domestic Council and the advisory bodies of scientists (who included outstanding experts as Sabin, Salk, Kilbourne and Davenport) have acted in good faith and proposed a program predicated on the limited information available in accord with their best judgments.

What is astonishing is the relatively limited discussion of all these relevant, valid issues either in Congressional hearings, in press editorials, or by the usual TV commentators. One would hope that if an epidemic does not occur that those who have had nothing to say to date on these points will have the decency to recognize their present silence after attaining 20-20 hindsight. It is easy to throw bricks at people in glass houses but very difficult to have to face the necessity of judgments relating to life and death—yourself.

The more imperative lesson to be learned from all this is the need for a new look at the dogma and rituals which have grown up in respect to the development and clearance of new therapeutic agents. We refer particularly to the virtually absolute rejection of expert opinion and judgment and even the practical exclusion of experiments of substantial evidence for efficacy, except for double-blinds, which are being applied even to new major life-saving medications.

"The recruit was seen in the dispensary and then assigned to his quarters for 48 hours. He left his bed before then to join a forced march at night with the

other recruits. Laggard behind, despite frequent rests, he eventually collapsed, was rushed to hospital where he died shortly thereafter.



"It's a nasty letter from the Pure Food and Drug people."

©1976, Medical Tribune, Inc.

...and Inaction Based on a Double Standard

THE LIKELIHOOD of a U.S. swine influenza epidemic in 1976-77 is estimated in a range from a low of 2% to a "probability of 10 percent, 35 percent, and less than even" (*Science*, May 14, 1976). Our epidemic of heart disease, both in respect to incidence and death, is very, very real—it exists now. It occurs not once every 50 years but year in and year out. The Assistant Secretary for Health, Dr. Theodore Cooper, has publicly recognized coronary and hypertensive heart disease as a national epidemic. There are over 750,000 American cardiovascular deaths annually. Compare this to "the 1918-19 pandemic which swept around the world . . . in successive waves [and] killed 548,000 Americans of all ages" (*Science*, May 14, 1976).

Despite this, not only are judgmental decisions rejected but significant data on efficacy of therapies, dosages, chronic toxicities and patient salvage, which are available, are disregarded in respect to critical new cardiovascular medicines. Certainly the use of beta-blockers to the extent of several tons

per month in Britain alone affords some assurance of safety as well as a body of experience in respect to efficacy. A range of life-saving beta-blockers available in such medically sophisticated and therapeutically monitored societies as Sweden and Great Britain has been denied U.S. doctors and patients for years—and continues to be held back. The flu vaccine situation should stand as a warning that when scientific decisions are left primarily or solely to the government, double or different standards can quickly prevail. The situation reinforces the conviction that in areas of medicine and health open debate must be preserved and government nonpartisanship and true objectivity must be a *sine qua non* of a democratic society.

The contrast between what the government says and what the government does is bewildering. Is not the time long past when government can, as it wishes, justify inaction on the basis of those very criteria which it rejects or disregards in respect to its own actions?

LETTERS TO TRIBUNE

Legally Speaking

Your editorial (MT, June 23), on the American Association of Trial Lawyers effort to bar the Medical Society of the State of New York from what it attempted to call "false advertising" when the Medical Society used an advertising supplement in New York State newspapers, has prompted me to respond.

The Society favored pending legislation which placed a ceiling on contingency fees and which would limit awards for pain and suffering. The Society also called the McGill Commission's report "impartial." According to the lawyers' association's standards, the Commission was not impartial since "five of the nine members of the Commission were at one time directly or indirectly connected with the medical profession and providers of health care."

The lawyers' association, when it petitioned the Federal Trade Commission, stated that the Society's advertising could be condemned for calling the McGill Commission "impar-

tial." Where is the evidence for this? Does a man's association with the medical profession make him incapable of impartiality? The answer to this question lies in the realm of intuition. Facts must be proven by other facts. Where are the Association's facts?

Supposing the Association, and not Governor Carey, would be given the responsibility of creating a Commission. Would they appoint lawyers to the Commission or engineers or housewives? The New York State Legislature is composed, in the majority, of lawyers. Are they incapable of impartiality?

The Association's procedural attack points up an irreconcilable difference in the thinking of doctors and lawyers. Had the positions been reversed, would a group of doctors have attacked the substantive aspects of the report rather than the composition of the Commission?

GEORGE A. FRIEDMAN,
M.D., J.D., LL.M.

Fellow,
American College of Legal Medicine

John McKee Project Manager
Vicki Morton Administration Manager
Isabel Hutchings Conference Manager
Charlotte Benton-Hughes Conference Assistant
Mary Brown Technical Services Manager

Surrey TW9 2LS

Tel: 081 332 2422
Fax: 081 332 0939

Scottish & Newcastle Br
Sellelapp GB Ltd
Seton Healthcare Group
Sheaffer Pen (UK) Ltd
Smith & Nephew
SmithKline Beecham
Somerville Stores
Sony United Kingdom
St Ivel Ltd
Stratford-Up-Avon
Tate & Lyle Sugars
Tearlon Cider plc
Telford Foods Ltd
Tesco Stores Ltd

"packaging
other exhibi
opportunity
to meet. M
not availab
chance to
discussing
new ideas
Kevin Hyde,
Wells Great

The Boots Co
The Cheese C
The Invergar
The Kerrygol
The New Cov
The Ryella C
The Wellcom
Thornons P
Thornons P
Tomy UK L
Tovall H
Trafford P
Tranfield
Treats Gr
Trebort B
Tulip Int
Vitamall
W A Tur
W Jorda
Wells G
Woolste
White A
Whitw
Wicke
Woolw

Purchasing

Purchasing
Management Manager
Buyer
Manager
Supply Chain Manager
Director

nts Ltd

or Mortlake Road

Ismelin® sulfate
(guanethidine sulfate)

Esmil®
guanethidine monosulfate 10 mg
hydrochlorothiazide 25 mg

WARNING
This fixed combination drug is not indicated for initial therapy of hypertension. Hypertension requires therapy directed to the individual patient. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. The treatment of hypertension is not static, but must be reevaluated as conditions in each patient warrant.

INDICATIONS
Ismelin
Moderate and severe hypertension either alone or as an adjunct.
Esmil
Hypertension. (See box warning above.)

CONTRAINDICATIONS
Guanethidine: Known or suspected pheochromocytoma; hypersensitivity; frank congestive heart failure not due to hypertension; use of MAO inhibitors. Hydrochlorothiazide: Anuria; hypersensitivity to this or other sulfonamide-derived drugs. The routine use of diuretics in an otherwise healthy pregnant woman with or without mild edema is contraindicated and possibly hazardous.

WARNINGS
Antihypertensives are potent drugs and can lead to disturbing and serious clinical problems. Physicians should be familiar with all drugs and their combinations before prescribing, and patients should be warned not to deviate from instructions.

Guanethidine
Warn patients about the potential hazards of orthostatic hypotension, which can occur frequently and is most marked in the morning and is accentuated by not wearing alcohol, or exercise. To help prevent falling, warn patients to sit or lie down with onset of dizziness or weakness, which may be particularly bothersome during the initial period of dosage adjustment and with postural changes. The potential occurrence of these symptoms may require alteration of previous daily activity. Caution patients to avoid sudden or prolonged standing or exercise while taking the drug.

Concurrent use with rauwolfia derivatives may cause excessive postural hypotension, bradycardia, and mental depression.

If possible, withdraw therapy 2 weeks prior to surgery to reduce the possibility of vascular collapse and cardiac arrest during anesthesia. If emergency surgery is indicated, administer preanesthetic and anesthetic agents cautiously in reduced dosage and have oxygen, atropine, vasopressors, and IV solutions ready for immediate use to treat vascular collapse. Vasopressors should be used with extreme caution in patients on guanethidine because of the possibility of augmented response and the greater propensity for cardiac arrhythmias.

Dosage requirements may be reduced in presence of fever. Exercise special care when treating patients with a history of bronchial asthma, since their condition may be aggravated.

Hydrochlorothiazide
Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte imbalance may precipitate hepatic coma.

Thiazides may be additive or potentiative of the action of other antihypertensive drugs. Potential interaction with ganglionic or peripheral adrenergic blocking drugs.

Sensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Usage in Pregnancy
Guanethidine: The safety of guanethidine for use in pregnancy has not been established; therefore, this drug should be used in pregnant patients only when, in the judgment of the physician, its use is deemed essential to the welfare of the patient.

Hydrochlorothiazide: Usage of thiazides in women of childbearing age requires that the potential benefits of the drug be weighed against its possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.

Nursing Mothers
Thiazides cross the placental barrier and appear in cord blood and breast milk.

PRECAUTIONS
Discontinue the effects of guanethidine are cumulative over long periods. Initial doses should be small and increased gradually. Use with caution in patients with renal disease and nitrogen retention. Use with caution in patients with coronary disease with myocardial or recent myocardial infarction, cerebral vascular disease, or aortic stenosis. Do not give guanethidine to

patients with severe cardiac failure and/or with extreme caution.

In patients with cardiac decompensation, weight gain or edema may be avoided by the administration of a thiazide. Remember that both digitalis and guanethidine slow the heart rate.

Use very cautiously in hypertensive patients with renal disease and nitrogen retention. Use with caution in patients with coronary disease with myocardial or recent myocardial infarction, cerebral vascular disease, or aortic stenosis.

Amphetamine-like compounds, stimulants (eg, epinephrine, norepinephrine, etc.), and other sympathomimetic amines (eg, amphetamine, desipramine) and other psychopharmacologic agents (eg, phenothiazines and related compounds), and oral contraceptives may reduce the hypotensive effect of guanethidine. Discontinue MAO inhibitors for at least one week before starting guanethidine.

Hydrochlorothiazide: Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals. Observe patients for clinical signs of fluid or electrolyte imbalance (hypokalemia, hyponatremia, etc.). Serum and

urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Medication such as digitalis may also influence serum electrolytes. Warning signs are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbance such as nausea or vomiting.

Hypokalemia may develop with thiazides as with any other potent diuretic, especially during brisk diuresis, when

severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

in moderate hypertension.

...most patients tolerate guanethidine with minimal side effects when dosage adjustment is carefully managed.

1. Freis ED: *The Modern Management of Hypertension*, US Government Printing Office, 1973, pp 13, 14.

Currently, there is a positive trend towards reevaluating Ismelin (guanethidine) for use in moderate hypertension.

Perhaps the most effective antihypertensive available, Ismelin offers convenient, once-a-day dosage—a major factor in encouraging patient compliance.

And, when given in moderated doses, guanethidine does not appear to present a major side effect problem.

When Ismelin is added to other antihypertensives, initial doses should

be small and increased gradually by small increments. Once blood pressure control is achieved, all drug dosages should be reduced to lowest effective level, often minimizing side effects.

Patients should be warned about the possibility of orthostatic hypotension and cautioned to avoid sudden or prolonged standing or exercise.

Please turn page for further options in treating moderate hypertension.

Doctors are rediscovering...

once-a-day
Ismelin®
(guanethidine)

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

with severe cirrhosis is present, or during concomitant administration of steroids or ACTH.

Interference with adequate oral intake of electrolytes will also contribute to hypokalemia. Digitalis therapy may exaggerate metabolic effects of hypokalemia, especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (eg, in liver disease or renal disease). Disturbing hyponatremia may occur in edematous patients

CIBA

Esimil

guanethidine monosulfate 10 mg
hydrochlorothiazide 25 mg

the once-a-day alternative

Esimil, the once-a-day alternative to methyldopa plus hydrochlorothiazide

Guanethidine and hydrochlorothiazide are highly effective and are usually well tolerated when administered together. Esimil, the combination of these two drugs, offers the additional advantage of being a once-a-day medication.

Doctors are reconsidering the advantages of treating moderate hypertension by referring to Esimil.

parosmia, headache, vertigo, purpura, photosensitivity, rash, urticaria, exfoliating angitis, Stevens-Johnson syndrome, and other hypersensitivity reactions. Hematologic—leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia. Cardiovascular—orthostatic hypotension may occur and may be potentiated by alcohol, barbiturates, or narcotics. Other—hyperglycemia, glycosuria, hyperuricemia, xanthine stones, weakness, restlessness. Whenever adverse reactions are moderate or severe, reduce dosage or withdraw therapy.

DOSEAGE AND ADMINISTRATION
Initial dosage should be low and increased gradually by small increments. Before starting therapy, consult complete product literature.
Esimil is determined by individual titration. (See box warning.)
Before starting therapy, consult complete product literature.
HOW SUPPLIED
Esimil Tablets, 10 mg (pale yellow, scored) and 25 mg (white, scored) bottles of 30, 60, 100 and 1000.

CIBA Pharmaceutical Company
Division of CIBA-Geigy Corporation
Summit, New Jersey 07901
References: 1. Fraile E. The Modern Management of Hypertension. US Government Printing Office, 1973, pp 13, 14.
2. Tarpley EJ. Controlled trial of guanethidine and methyldopa in moderate hypertension. *Curr Ther Res* 16:1187-1195, 1974.
3. Niles AS. Adverse reactions and interactions limiting the use of antihypertensive drugs. *Am J Med* 58:495-505, 1975.
4. Briggs AH, Holland WD. The cardiovascular system. Antihypertensive drugs. In: *Diagnosis, JR (ed). Drug's Pharmacology in Medicine*, ed 4. New York, McGraw-Hill Book Co, 1971, pp 853-868.
5. Langford HG. Hypertension, in: *Com*

HP (ed). *Current Therapy* 1973. Philadelphia, The WB Saunders Co, 1973, p 201.
6. Glazer N. Comparison of guanethidine and methyldopa in essential hypertension: A controlled study. *Curr Ther Res* 17:249-256, 1975.

C I B A

Wednesday, August 4, 1976

MEDICAL TRIBUNE

15




lysis unit is staffed around clock by a pediatric nephrologist and two RNs. On duty here (l. to r.): Sheryl Melber, Children's Hospital, Detroit; Liz Aglipay, Mt. Sinai Hospital, N.Y.C.; Dr. George Schwartz, Einstein.

Only Camping Program For Children on Dialysis Now in Its Second Year


YOUNGSTERS with kidney failure can be like "other kids" and go off to summer camp at a facility equipped with a four-bed dialysis unit at Frost Valley YMCA camp in Oilton, N.Y. Opened last year and so far the only one of its kind, the camp operates as a satellite of the Hospital of the Albert Einstein College of Medicine in New York. Dr. Ira Orloff, Director of Pediatrics and of the Children's Kidney Center of the Hospital, says the innovative program enables children aged 7 to 16 on maintenance dialysis to enjoy a two-week normal camping experience unavailable before.



Horseback riding ranks high among the favorite outdoor activities available during the eight-week program, which has an enrollment this summer of 32 children.



Each child undergoes dialysis three times a week, with the four- to five-hour procedure fitted as unobtrusively as possible into the schedule of camp-life activities and social contacts.



Hours on dialysis seem shorter with a friend around. This year, program has added a week for children under 7 with their parents.



Companionship with others having the same disease—and similar problems—is big plus for young dialysis patients who usually meet each other only in hospital or clinic setting.

Julian Gorsi Project Director
John McKee Project Manager
Vicki Morison Administration Manager
Isabel Hutchings Conference Manager
Charlotte Benton-Hughes Conference
Kerry Brown Technical Secretary

Scottish & Newcastle
Seton Healthcare Gr.
Sheaffer Pen (UK) Ltd.
Smith & Nephew
SmithKline Beecham
Somerset Stores
Sony United Kingdom
Staveland Ltd.
Stratford-Up-Avon
Tate & Lyle Sugars
Taunton Cider plc
Telford Foods Ltd.
Tesco Stores Ltd.

"packaging"
other exhibi
opportunit
to meet.
not availa
chance to
discuss
new ideas
Kevin Hyde
Wells Green

The Boots
The Cheese
The Inverg
The Korry
The New
The Ryvill
The Welle
Thornton
Tommy UP
Tovall H
Trafford
Tranfield
Treats
Trebort
Tullip
Vitamin
W A T
W Jor
Wells
West
Whit
Whit
Wic
Wor

chasing
chasing
ment Manager
Buyer
ager
Chain Manager
Director

Ltd
Mortlake Road
TW9 2LS

1 332 2422
1 332 0939

Microsurgery Successful in Testis Autotransplant

Medical Tribune Report

PHILADELPHIA—In what is believed to be the first successful operation of its kind, an intra-abdominal testis in a nine-year-old boy has been transplanted to the scrotum using a microvascular surgical technique, a San Francisco urologist reported here. "Al-

though the long-term results regarding fertility will not be known for many years, the immediate results appear good," Dr. Sherman J. Silber told a seminar of the International Society of Pediatric Urologists.

"No testicular atrophy is detectable on palpation," Dr. Silber said. "Good

pulsation was noted immediately in the spermatic artery, and venous drainage was excellent. Without microvascular orchidopexy, the testis would have been removed or allowed to remain in the abdomen, where an occult neoplasm might have developed. With our technique, a viable testis was preserved in a position favorable for future observation."

Reversed Vasectomies

Dr. Silber, who last year reported a 60% success rate in a new microsurgical technique for reversing vasectomies (MT, Nov. 19, 1975), is Associate Professor of Urology at the University of California, San Francisco, and Chief of Urology at the Veterans Administration Hospital there. His associate and coauthor both in the vasectomy reversals and in this testicular autotransplant has been Dr. Justin Kelly, of Royal Children's Hospital, Melbourne, Australia.

"One to 5% of cryptorchid testes are intra-abdominal and cannot be properly brought down into the scrotum by conventional methods," Dr. Silber said. "In such cases, necessary division of the spermatic vessels results in risk of testicular ischemia. We at-


tempted to solve this problem by microanastomosis of the spermatic vessels to the inferior epigastric vessels in the groin." The autotransplant procedure not only allowed tension-free placement of the high testis, originally located just below the kidneys, into the scrotum, but also provided an adequate blood supply.

This experience with testicular autotransplantation suggests that the microsurgical technique may be applicable in the transplantation of testes from one individual to another, Dr. Silber told MEDICAL TRIBUNE. "Now that it's been shown that the blood vessels can be rejoined, and that reversal of vasectomy has been perfected—these are the only three hook-ups you need—it is going to be very easy to transplant a human testicle and preserve its function."

"One indication would be where the male is infertile and his religious beliefs prohibit artificial insemination," he said, adding that this may apply to Moslems and Orthodox Jews.

"Another indication would be for a man who lost his testes in an accident or was born anorchid, who might seek a transplant instead of going on male hormones for the rest of his life."

"This is an interesting speculation—but it hasn't been done yet," Dr. Silber concluded.



Abdominal testis, left, was severed from vena cava and aorta, placed in scrotum, right, and attached to inferior epigastric artery and saphenous vein.

Low Cardiac Output May Resemble Hepatitis

By NATHAN HORWITZ

Medical Tribune Staff

MIAMI BEACH—A lesion that presents clinically as hepatitis but is, in fact, due to low cardiac output stemming from left-sided heart failure, was described here by a Boston team.

The syndrome, which occurs without pulmonary congestion, may not be uncommon in patients with low cardiac output, the investigators suggested.

The new entity was identified in five individuals who had neither hypotension nor right-sided congestive heart failure—well-documented links to overt liver disease, said Dr. J. A. Cohen of the New England Medical Center Hospital.

Hepatitis was initially suspected in the five patients because of anorexia, nausea, and fatigue in two cases and "striking" unexplained transaminase elevations in three, Dr. Cohen told the American Association for the Study of Liver Diseases. Each of the patients had a history of heart disease, but an experienced cardiologist described each, after examination, "as well compensated and without signs of congestive failure." And, said Dr. Cohen, "The cardiologist concluded that the liver dysfunction was unrelated to the heart disease."

Decrease Documented

Liver biopsy in all patients revealed central liver necrosis, but in none was there histologic evidence of hepatitis or of passive congestion. The hepatitis surface antigen was negative in the three patients in whom it was tested; the investigator continued: There was no neck vein distension in the group, and peripheral and central venous pressures were normal.

Decreased cardiac output was then

documented in one patient by echocardiogram and in another by cardiac catheterization. In the first case, that of a 61-year-old man with atherosclerotic coronary artery disease, echocardiography was performed "because of the strong clinical impression that this patient's heart disease was not severe enough to cause the liver disease," Dr. Cohen said. The patient had been admitted with a six-week history of anorexia, fatigue and a 12-pound weight loss. But he was not hypotensive and had no signs of congestive failure, Dr. Cohen stressed. Echocar-

diography, however, revealed "poor myocardial contractility and a very low systolic ejection fraction of 15%."

In the second patient, a woman with rheumatic heart disease, cardiac catheterization for evaluation of increasing exertional dyspnea had been delayed because of unexplained high transaminase levels. When the procedure was ultimately performed it revealed a normal right atrial pressure, a "strikingly low cardiac index of 1.4 and critical mitral stenosis." After mitral valve replacement, the transaminase levels rapidly returned to normal.

Pulmonary Lavage Method May Replace Lung Biopsy

Medical Tribune Report

NEW ORLEANS—Bronchofiberscopic subsegmental pulmonary lavage is a safe and accurate means of evaluating immunosuppressed patients suspected of having pneumocystis pneumonia—the most common cause of diffuse pulmonary infiltrates in such patients—and may preclude the need for open lung biopsy, Dr. Jason Kelley, a Pulmonary Fellow at the University of Vermont, told the American Thoracic Association.

Other low morbidity diagnostic methods, such as bronchial brushing, percutaneous needle biopsy or aspiration, and endobronchial forceps biopsy have yielded a "significant number of false negative results," Dr. Kelley said. When findings are negative in the face of a strong diagnostic presumption, physicians have had to weigh whether to expose immunosuppressed patients, who are frequently physiologically unstable, to the anes-

thetic and surgical risks of open lung biopsy or institute empiric drug therapy, he stated.

Since pulmonary lavage specifically samples the alveolar space, where pneumocystis disease occurs, the technique was employed, following initial animal studies, on a trial basis in 15 patients in whom progressive pneumonia and fever suggested pneumocystis or other opportunistic pathogens. Three proved to have pneumocystis by lavage, and 12 showing negative results had either leukemic infiltrates, bacterial pneumonia, viral pneumonia, connective tissue disease or chemotherapy-induced fibrosis, confirmed by tissue diagnosis, bronchoscopic culture or response to altered chemotherapy.

"We were not compelled to perform open lung biopsy in any case," Dr. Kelley reported, and no patient with a negative lavage received pentamidine, the current drug of choice for treating pneumocystis infection. The drug may

produce hypoglycemia, renal failure or pain at the site of injection, Dr. John Landis, principal investigator and Associate Director of Medical Services, the Medical Center of Western Massachusetts, noted in an interview.

The sole patient with a negative lavage who died did not have evidence of pneumocystis at autopsy.

Procedure 'Very Safe'

Later employed in over 100 patients and normal volunteers, bronchofiberscopic pulmonary lavage proved to be a "very safe procedure," Dr. Kelley continued. The two major risk factors encountered were hypoxemia and thrombocytopenia, but neither were considered contraindications. Seven hypoxic patients received supplemental oxygen during the procedure. In five thrombocytopenic patients, no bleeding episodes occurred during bronchoscopy. Two patients receiving ventilatory support via nasotracheal tube prior to bronchoscopy and 100% oxygen during the procedure died of bacterial superinfection unrelated to respiratory support at least seven days after pulmonary lavage.

New Camera Enables Bedside Nuclear Scan

Medical Tribune Report

DALLAS—A newly developed portable nuclear scanning camera allows radiologic procedures to be brought to the bedside of critically ill patients, Dr. John A. Burdine, Professor of Nuclear Medicine, Baylor College of Medicine in Houston, reported here. The new Low Energy Mobile (LEM) camera was unveiled during the Society of Nuclear Medicine's annual meeting.

Dr. Burdine conducted clinical trials with the LEM over a four-month period involving 150 patients in St. Luke's Episcopal and Texas Children's Hospitals in Houston.

He found that the camera increases diagnostic capabilities without compromising patient safety and comfort. He predicted that the unit will probably receive wide acceptance in cardiology, pediatrics, and orthopedics, where movement of the patient may be undesirable.

"While the usefulness of nuclear imaging procedures in the care of the critically ill is well understood, many of these patients are confined to cir-



Low Energy Mobile portable nuclear camera, developed by the radiographic division of G.D. Searle & Co., allows all routine radiologic procedures to be performed at bedside, reducing patient movement and discomfort to a minimum.

cumstances where they cannot be transported to the nuclear medicine laboratory," Dr. Burdine said.

"With LEM, virtually all routine nuclear imaging procedures utilizing low energy radiopharmaceuticals may be

performed at the patient's bedside." The LEM camera, made by the radiographic division of G.D. Searle & Co., weighs 790 lbs., has a 250 kilo electron volt energy limit, and can do 80% of a standard camera's work.

Effect of Irradiation in Cancer: An Issue at Radium Society

Medical Tribune World Service

VANCOUVER, B.C.—The controversy regarding the clinical and prognostic significance of immunosuppression in irradiated cancer patients received wide attention here at the Fifty-Eighth Annual Meeting of the American Radium Society.

Does radiation therapy itself cause significant suppression of cell-mediated immunity? Yes and no, implied Dr. Charles McKhann, Professor of Surgery at the University of Minnesota. His studies of 150 melanoma and sarcoma patients show that they already had depressed immune responses, as measured both by T-cell rosette formation and by phytohemagglutinin (PHA) lymphocyte stimulation.

But this immunologic depression is intensified by current treatment modalities, Dr. McKhann said. Surgery, or possibly the anesthesia used with it, dampens cell-mediated immunity for a matter of days, and chemotherapy for weeks or months. Irradiation, he said, appears to dampen it for years.

Tests Too Sensitive?

Yet the clinical significance of such findings is not clear, Dr. McKhann pointed out. "We see T-cell depression in normal persons with a cold." Perhaps the T-cell rosette formation and PHA lymphocyte stimulation tests are "too sensitive." There are different subpopulations of T-cells, but it is not known which is "protective." In any event, investigators "don't know exactly" what their findings mean.

The need for more definitive data was also cited by Dr. William M. Wara, Assistant Professor of Radiation Oncology, Division of Radiation Oncology, University of California, San Francisco, who reviewed the pertinent scientific literature.

The "most controversial report" in the literature to date, Dr. Wara said,

is that of Dr. Jan Stjernswärd (*Lancet* 1:1352, 1972), who attributed depressed cell-mediated immunity in breast cancer patients to irradiation of the thymus. This interpretation has "recently been challenged" by other investigators who have not only questioned "the statistical validity" and "follow-up time" of Dr. Stjernswärd's studies, but also "demonstrated that inclusion of the thymus gland in the irradiated field was not a prerequisite for subsequent immunosuppression."

Immunosuppression in irradiated patients has now been well documented, Dr. Wara said, but he agreed with Dr.

McKhann that its significance "remains unclear." Accordingly, Dr. Wara raised two questions which he felt would serve to clarify the clinical issues in radiation therapy for neoplastic disease: "Is depressed T-cell immunity as evaluated in vitro related to patient prognosis and survival? And can this immunosuppression be altered by immunotherapy?"

"Clearly," he concluded, "prospective controlled trials must be initiated to evaluate the effects of localized irradiation on lymphocyte subpopulations, as well as the effect of immunotherapy (BCC, transfer factor, levamisole, thymosin, etc.) on these patients. Only with these studies will we be able to determine the length and prognostic significance of immunosuppression caused by irradiation."

Partial Cystectomy Proves Useful in Some Bladder Ca

Medical Tribune Report

LAS VEGAS—Partial cystectomy may be equally as effective as total cystectomy in treating primary and secondary carcinoma of the bladder, a Cleveland Clinic team told a meeting of the American Urological Association.

Advocates of partial cystectomy cite as advantages: technical simplicity, diminished morbidity and mortality rates, and preservation of continence and potency. Proponents of radical surgery argue that partial cystectomy represents less than adequate treatment in terms of survival and ultimate cure rate, Dr. Andrew C. Novick explained.

Fifty patients underwent partial cystectomy as the primary means of treatment in the period from 1960 to 1972. The five-year survival rate was 67% for Stage O-A, 53% for Stage B, and 20% for Stages C and D1 combined, which compares "most favorably" with total cystectomy outcomes, according to Dr. Novick and Dr. Bruce H. Stewart, of the Department of Urology.

Dr. Novick added that patients in whom free margins of resection were accom-

plished for unifocal disease achieved longer survival with less chance of developing recurrent bladder cancer.

12-Year Study

The 12-year study involved 43 males and seven females, with an average age of 64 years, who underwent partial cystectomy at the Cleveland Clinic and included all tumor types, Dr. Novick said. He added that during this period an additional 12 patients underwent partial cystectomy as adjunctive surgical treatment for primary gastrointestinal or gynecologic malignancies secondarily invading the bladder. Less favorable results were reported for this group of patients.

Patients with primary bladder carcinoma were considered for partial cystectomy under the following conditions: where tumors were confined to the bladder dome; tumors within a bladder diverticulum; solitary tumors overlying a ureteral orifice and/or involving the distal ureter; tumors not amenable to transurethral resection; and tumors in poor-risk patients.

Correcting Immunodeficiency

"... Owing to the laws governing the inheritance of the major histocompatibility antigens... a majority of infants [with severe combined immunodeficiency] will have no compatible potential donors [of bone marrow for transplantation]. The repeated dramatic reversal of the uniformly fatal prognosis in the disorder by grafts of compatible marrow cells over the past eight years has prompted the intensive search for alternative forms of definitive therapy when no histocompatible donors exist; with few exceptions, these efforts have been unsuccessful. In [our studies of] two unrelated male infants... fresh, very young fetal liver cells were used in attempted immunologic correction of the adenosine deaminase positive form of severe combined immunodeficiency. The observation of transient graft-versus-host disease in both infants documents the graft-versus-host potential of even this very young fetal tissue. More importantly, the successful immunologic reversal of the immunodeficiency in one of the infants confirms the usefulness of fetal liver cells as an alternative form of definitive therapy when bone-marrow transplantation cannot be performed." (Rebecca H. Buckley, et al, *New Engl. J. Med.* 294:1076, May 13, 1976)

Mark...
Julian Gorst Project Director
John McKee Project Manager
Vicki Morrison Administration Manager
Isabel Hutchings Conference Secretary
Charlotte Benton-Hughes

Surrey TW9 2LS

tel: 081 332 2422
fax: 081 332 0939

Scottish & Newcastle
Seton Healthcare Group
Sheaffer Pen (UK) Ltd
Smith & Nephew
SmithKline Beecham
Somerset United Kingdom
Sony United Kingdom
St Ivel Ltd
Stratford Upon-Avon
Tale & Lyle Sugars
Taunton Cider plc
Telford Foods Ltd
Tesco Stores Ltd

"packaging
other exhi
opportunit
to meet
not avail
chance to
discussin
new idea
Kevin Hyde
Wells Gre


The Boots
The Cheese
The Inverg
The Kerry
The New
The Ryvill
The Wellc
Thornston
Thornston
Tomy UK
Toys H
Trafford
Tramline
Treats
Trebor
Tulip
Vitam
W A T
W Jon
Wells
West
White
White
White

Chasing

Marketing Manager
Buyer
Sager
Chain Manager
Director

Ltd

Mortlake Road



China: Trees and Art, Technology and Ecology

I HAVE COMMENTED ON Allan Chase's observations on the medical ecologic bi-centennial of Sir Percival Pott's observation on coal soot, the cause of scrotal cancer in chimney sweeps. Our discussion ranged much wider. We agreed on the fallacies and dangers of neo-Malthusian doctrines; we wondered at the marvel of our industrial nation producing enough food both for ourselves and for scores of millions around the world with just 4% of our own population. Our discussion turned to the ability of the People's Republic of China to feed almost a quarter of the world's population, about three-quarters of a billion souls, sans our technology or mechanization.

I have long been interested in the archaeology and art of China and fascinated with their discoveries preceding those of the West in technology and in aesthetics. One has to see, to fully enjoy and believe, the solutions that Chinese painters achieved several hundred years before Cezanne, the Impressionists and even the Expressionists. Knowing of my interests, Allan couldn't resist telling me about a recent experience of his own.

Recurrent Theme

His sister and her husband had just returned from China. As he had suggested to them, they recorded the events of the day each evening. Allan had the opportunity of listening to the tapes in a few sittings. He noted a recurrent theme—again and again reference to the planting of trees, to the dispersion of factories, plants of small size sited in relation to an agricultural commune. It appeared that in contrast to the West which introduced the technology of the Industrial Revolution, there may be a difference in approach to mass production in today's China. Even as large-scale facilities are being built, as for manufacture of steel or generation of hydroelectric power, the Chinese appear to be significantly decentralizing and fostering small-scale manufacturing enterprises. The implications inherent in massive reforestation and in industrial decentralization raise many fascinating conjectures.

Admiration of Nature

With respect to reforestation, there has been extensive mobilization of the population ever since the Chinese communist revolution. The floods of China have constituted an historic tragedy with recurring devastation and disruption, disease and death. But can it not be that the reforestation of China is much more than just flood control? Have the Chinese leaders, consciously or unconsciously, mobilized men, women and children to the task of harnessing solar energy through the medium of chlorophyll and storing it in their forests?

I have long been sensitive to the Chinese admiration of nature, to their fascination with landscape. Their pictorial presentations relating to the phys-

ical and aesthetic qualities of bamboo had brought much of their painting close to my heart and awakened a passionate love of the aesthetic of Chinese calligraphy.

The Chinese philosophy, the way of thinking implicit in Chinese art, Chinese absorption with the multifaceted aspects of nature as reflected in the interweaving of multiple forms and themes into their iconography, may carry over in some measure to their approach to science and technology. Their art and poetry would quickly reveal the very pointed pleasure they derive from actions with a complex of significances. This may be true also for reforestation with its aesthetic effects on the landscape, its practical application as in flood control, its other pragmatic advantages in the creation and storage of natural resources and, come to think of it, even its biochemical benefits in ecologic terms—the conversion of carbon dioxide into oxygen.

Balanced Biosphere

The concept of life cycle and that of a balanced biosphere goes back millennia in China. It well reflects their realism and their empiric solutions which have contributed so much to the Chinese understanding and positive use of nature. Han ceramics recorded social customs at the time of Christ and one of them shows a piggy bank on a "balanced sty" rather than a "balanced aquarium." The pig ate "night soil" and the pig in turn was eaten. Night soil was also used to fertilize the fields whose bean sprouts and vegetables were so important a part of the Chinese diet. The cycle of food reflected a cycle of life.

Allan pointed out in relation to the dispersion of factories another interesting gain—the dilution of potential pollutants. As in so much of Chinese custom and action, we must go beyond a simplistic unitary motivation and even beyond the potential military implications: placing small factories in relation to agricultural communities is both time- and material-saving. Commuting to work, so much a part of the urbanized, industrialized western societies, is reduced if not eliminated. The physical state of the worker is improved by walking or pedaling a bicycle rather than by the application of the gas pedal of a car. Decentralization contributes more than a saving of time and the benefits of physical exercise. It reduces


the waste of metals and fuel consumed and toxic pollutants produced by cars, buses and trains.

True Progress of Man

We can't avoid making comparisons and we must stress the danger of unidimensional thinking. It is high time we stopped looking at the problems of the world solely in terms of population numbers. With one-quarter of the population of China, our industrial plant can produce multiples of the environmental pollutants they do. Worse than that, we have replaced the biological benefits of man's excreta with the non-biodegradable and highly toxic "excreta" of an industrial society which can poison not only its soil and water but its people as well. Nature is remarkable—if we do not tortuously distort its cycle, as we unnecessarily do by unthinking industrialization. An automobile created by man pollutes. The natural by-products of man qua man, properly used, enriches. It cannot be that the Chinese will stand alone in recognizing that nature affords us a closed system in which man can physically as well as intellectually and spiritually live well, even as he enriches his world. There is nothing in our philosophy and there is much in our history which says that we, too, can meet the challenge and assure that industrial and technologic progress is tied, in more of its aspects, to the true progress of man.

Medicine on Stamps

Oliver Wolcott



Oliver Wolcott (1726-1797) was born in Windsor, Conn. Shortly after graduating from Yale, he was commissioned in the militia and served in the "King George's War." He then studied medicine as an apprentice to his brother. His medical career was rather limited, since he served as Army Surgeon only during the campaign against Burgoyne in 1775. He remained in public service for the rest of his life. In 1776 he was elected to the Continental Congress and is pictured in the above stamp as one of the signers of the Declaration of Independence. He is the 41st member from the left. He was elected Governor of Conn. in 1796 and served until his death. The nation's Bicentennial coincides with the 250th anniversary of his birth.

From Dr. Joseph Kler
Stamp: Makus Publications, Inc., New York

EDITORIAL CAPSULES

... brief summaries of editorials or comments in current medical and scientific journals.

Need for Holistic Medicine

"The inability of physicians, psychiatrists included, to practice a genuinely holistic medicine that integrates knowledge of the body, the mind, and the environment is striking. Psychiatrists, for example, tend to adhere to one or another of the various ideologies in their field and to ignore the others; in spite of advances in neurochemistry and genetics, these disciplines often get little attention from psychiatric practitioners or training programs. Nonpsychiatrist physicians mainly interested in disease or dysfunction of a particular organ-system ignore the unaffected systems and the psyche.

"These attitudes persist despite pages of polemics about the importance of treating the whole person, and despite overwhelming evidence that a comprehensive understanding of man requires a general systems approach.

"Medicine must be an adaptive system of learning. Just as we expect people to be mature and effectively coping individuals, we must have the courage and the determination to study the forces that produce and maintain health and well-being, not merely the forces that produce disease.

"A failure to explore and counter the forces that sustain these dualistic splits will permit them to retard the development of a general systems approach by discouraging the transfer of information from neurophysiology to psychoanalysis, from small group and family dynamics experience to general practice, from neurochemistry to clinical psychiatry, from the social and behavioral sciences to general medicine, and so on and on. Pertinent knowledge will remain in the hands of the researchers and the universities and have virtually no impact at all on the physician and his practice. Under these conditions, medicine will see still further lowering of its status in the public eye. Our dissatisfied or unsatisfied clientele will search elsewhere, leaving us open to the charge that we are more interested in protecting our traditions than helping our patients.

"Breaking the grip of these dualities will permit medicine to recapture the whole person as the focus of attention and reduce those dehumanizing preoccupations with the disease alone, the psyche alone, the liver or the pancreas alone, the psychosis alone. This is holistic medicine for a society that needs to learn from the medical profession how to be an effectively caring society." (Editorial, Roy W. Menninger, M.D., Ann. Int. Med. 84:604, May, 1976)

EPIGRAMS—Clinical and Otherwise

Not know that what disturbs our blood
Is but its longing for the tomb.

William Butler Yeats
(1865-1939)
The Wheel

Sitting pretty for years to come...

Gentle in bringing patients down to normotensive levels, Esidrix will continue to "sit right" with many of the mild hypertensives for whom you prescribe it. Indeed, it can mean years and years of even, uneventful control.

Esidrix. It is still unsurpassed as a basic diuretic/antihypertensive.

And many patients with edema rarely need a more potent diuretic.

Contraindications include anuria. Use cautiously in patients with impaired renal or hepatic function.



Esidrix®
(hydrochlorothiazide)
for year-after-year control
of mild hypertension

Esidrix® (hydrochlorothiazide)

INDICATIONS

Hypertension and edema.

CONTRAINDICATIONS

Acute hypersensitivity to this or other sulfonamide-derived drugs. The routine use of diuretics in otherwise healthy pregnant women with or without mild edema is contraindicated and potentially hazardous.

WARNINGS

Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte imbalance may precipitate hepatic coma.

Thiazides may be additive or potentiative of the action of other antihypertensive drugs. Potentiation occurs with peripheral or peripheral adrenergic blocking drugs.

Sensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Usage in Pregnancy
Thiazides in women of childbearing age require that the potential benefits of the drug be weighed against its possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions which have occurred in the adult.

Nursing Mothers
Thiazides cross the placental barrier and appear in cord blood and breast milk.

PRECAUTIONS
Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals. Observe patients for clinical signs of fluid or electrolyte imbalance (hypotension, hypochloremic alkalosis, and hypokalemia). Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Medication such as digitalis may also influence serum electrolytes. Warning signs are dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbance such as nausea or vomiting.

Hypokalemia may develop with thiazides as with any other potent diuretic, especially during brisk diuresis, when severe cirrhosis is present, or during concomitant administration of steroids or ACTH. Insulin therapy may also contribute to hypokalemia. Digitalis will also contribute to hypokalemia. Hypokalemia especially with reference to myocardial activity.

Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease). Distal renal hypotension may occur in edematous patients in hot weather; appropriate therapy is water restriction rather than administration of salt, except in rare instances when the hy-

ponemia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice.

Transient elevations in plasma calcium may occur in patients receiving thiazides, particularly in those with hyperparathyroidism. Pathological changes in the parathyroid gland have been reported in a few patients on prolonged thiazide therapy.

Hyperuricemia may occur or frank gout may be precipitated in certain patients. Insulin requirements in diabetic patients may be increased, decreased, or unchanged. Latent diabetes may become manifest during thiazide administration.

Thiazide drugs may increase the responsiveness to tubocurarine. The antihypertensive effects of the drug may be enhanced in the post-sympathectomy patient. Thiazides may decrease arterial responsiveness to norepinephrine. This is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.

If nitrogen retention indicates onset of progressive renal impairment, consider withholding or discontinuing diuretic therapy.

Thiazides may decrease serum PBI levels without signs of thyroid disturbance.

ADVERSE REACTIONS
Gastrointestinal—nausea, gastric irritation, nausea, vomiting, cramping, diarrhea, constipation, jaundice (intrahepatic cholestasis), pancreatitis, Central Nervous System—dizziness, vertigo, paresthesias, headache, xanthopsia, Dermatologic—photosensitivity—purpura, photosensitivity, rash, urticaria, necrotizing angitis, Stevens-Johnson syndrome, and other hypersensitivity reactions.

Hematologic—leukopenia, agranulocytosis, thrombocytopenia, aplastic anemia. Cardiovascular—orthostatic hypotension may occur and may be potentiated by alcohol, barbiturates, or narcotics. Other—hypoglycemia, glycosuria, hyperuricemia, muscle spasms, weakness, restlessness. Whenever adverse reactions are moderate or severe, reduce dosage or withdraw therapy.

DOSEAGE
Individualize dosage by titrating for maximum therapeutic response at the lowest possible dose. Hypertension (mild)—Usual dose 75 mg daily. Maintenance—After a week dosage may be adjusted downward to as little as 25 mg or upward to as much as 100 mg daily. Combined therapy—When necessary, other antihypertensives may be added gradually and with caution because of the potentiating effect of this drug. Dosages of ganglionic blockers should be halved.

Edema (initial)—25 to 100 mg daily for several days. Maintenance—25 to 100 mg daily or intermittently. Refractory patients may require up to 200 mg daily.

SUPPLIED
Tablets, 50 mg (yellow), scored; bottles of 30, 60, 100, 1000, 5000 and Accu-Pak blister units of 100. Tablets, 25 mg (pink, scored); bottles of 30, 60, 100, 1000 and 5000.

Consult complete literature before prescribing. CIBA Pharmaceutical Company, Division of CIBA-GEIGY Corporation, Summit, New Jersey 07901

C I B A

Mark Kohn Project Director
Julian Gors Project Manager
John McKee Project Manager
Vicki Morison Administration Manager
Isabel Hutchings Conference Manager
Charlotte Banton-Hughes Conference Ass.
Services Manager

Richmond
Surrey TW9 2LS
Tel: 081 332 2422
Fax: 081 332 0939

Scottish & Newcastle
Sollatope GB Ltd
Soton Healthcare Group
Sheaffer Pen (UK) Ltd
Smith & Nephew
SmithKline Beecham
Somerfield Stores
Sony United Kingdom
St Ivel Ltd
Stratford Upon-Avon
Tate & Lyle Sugars
Taunton Cider plc
Telford Foods Ltd
Tesco Stores Ltd

"packaging
other exhibit
opportunities
to meet
not available
chance to
discussing
new ideas
Kevin Hyde
Wella Group

The Boots Co
The Choise
The Invergo
The Karygo
The New Co
The Ryte
The Welles
Thornton
Thornton
Tomy UK
Tovall He
Traillor
Treats Co
Trebor
Tulip In
Vitame
W A Tu
W Jor
Wella
Westl
Whit
Wick
Woo

sing
sing
nt Manager
ayer
ar
heim Manager
ractor

ortlake Road

Harvard Community Brewing 'Genetic Engineering' Storm

Continued from page 3

"It's a cooling off period so that the council can hear evidence in a non-crisis situation," Mr. Pat Centanni, assistant to the Mayor, told MEDICAL TRIBUNE. "After that, we'll see."

The Harvard situation promises not to be an isolated incident but an augury of the future. A resolution before the Energy and Environment Committee of the U.S. Conference of Mayors proposes that investigators planning to perform any recombinant DNA research first notify the mayor and the legislative body of the community of their intentions. The resolution's sponsor? Mayor Alfred E. Vellucci, of Cambridge.

The public and political furor which threatens to engulf recombinant research distresses many scientists. They point out that all investigations have attendant risks. The impact of recombinant technology on society was a focal point of a recent Miles Laboratory-sponsored symposium held at MIT. MEDICAL TRIBUNE spoke with some of the participants.

No 'Fail-Safe' Research

"Recombinant DNA is a subset of a larger category of work," said geneticist Seymour Lederberg, Ph.D., of Brown University, Providence, R.I. "We've been working with animal DNA and viral DNA for roughly a generation. And in many cases recombinant DNA is safer to work with."

"Much of the time, we're working with a fraction of the viral genome and deliberately so. The overall impact of recombinant research may in many cases be to reduce risks," he told MEDICAL TRIBUNE.

"Take the example of producing vaccines against viral illness. We now have a crash program to produce a vaccine against swine influenza. To make the vaccine, large volumes of the virus must first be manufactured."

"If we had the gene for the protein coat of influenza virus—that's the only thing we actually need to produce the vaccine, it could be incorporated into E. coli. The bacterial cell would then make the influenza protein we're interested in. It wouldn't make the virus itself," he explained.

"I don't mean to minimize the hazards of DNA research. There's no such thing as fail-safe research. Despite the safeguards and the guidelines which have been set up, I'm assuming there will be human mistakes. It's plausible," he continued.

"But there's a trade-off. If we're so concerned about possible dangers, we might seriously consider expunging hospitals from cities. After all, they're a focal point of contagious and dangerous illness. But that's not very realistic, is it?"

Some critics argue that the information resulting from recombinant experiments could be obtained other ways.

"Well, yes and no," said Roy Curtiss, III, Ph.D., of the University of Alabama, Birmingham. "In some areas, for example in purifying eukaryotic genes, we don't have another way of extracting the information. In other areas, it's a judgmental opinion. Another technique might take longer,

involve greater expense and give potentially less resolution.

'Accelerated Knowledge'

"In my own field, recombinant technology has accelerated our knowledge of replication of information in microorganisms. Certainly it could have been obtained by other methods. But with recombinant research we've learned three to four years worth of information about E. coli in only one year," he explained.

"It's going to be up to the investigator to make a decision whether recombinant DNA is the best approach," said Stanley Falkow, Ph.D., of the University of Washington in Seattle. "And despite all the indications we have, very likely this research will not be particularly hazardous."

Dr. Falkow believes that the "biggest biohazard is likely to be ignorance" of good laboratory technique among the investigators and their staff. Dr. Curtiss agrees.

"The probability of a catastrophic occurrence is minuscule where one uses a disarmed host-vector system, that is, a strain of bacteria which has been so weakened that it cannot survive outside of laboratory conditions," Dr. Curtiss told MEDICAL TRIBUNE. (He has developed two such strains of E. coli, labeled 1776 and 1876 in honor of the nation's bicentennial. "We're working on 1976," he said.) "Of course, the probability figures in no way factor in human error, ranging from sloppy technique to mistakes in judgment."

"There is a tendency for people doing this research to be molecular biologists and biochemists without a great deal of training in microbiology or microbiological techniques," Dr. Falkow notes. "It's surprising how much basic microbiology they don't know," echoes Dr. Curtiss. "We've had dealings with a lot of labs wanting to use our strains. But they can't get the bug to grow or transform."

As a remedy, basic courses in microbiological technique are being conducted at the University of Minnesota, Cold Spring Harbor, and at NIH facilities, according to Dr. Falkow.

Talk of 'Monsters'

Dr. Lederberg, for one, however, believes that the press, with its talk of "monsters" escaping from the laboratory, has oversold the dangers of recombinant DNA research to the public. "The most notorious aspect of a story becomes the most glamorous," he says, a thought seconded by Dr. Stanley Cohen, of Stanford University.

"The news media with its emphasis on all or nothing research is laboring under a misconception," Dr. Cohen told MEDICAL TRIBUNE. "Everyone agrees that certain experiments should not be carried out. But I don't know one responsible scientist who wants to see this research halted."

Dr. Cohen is quick to point out that it was the researchers themselves who first noted the hazards of recombinant research and in a fairly drastic, although not unprecedented move, declared a voluntary moratorium on some experiments while guidelines for



Dr. George Wald, Nobel prize winner (1967) in physiology and medicine and Higgins Professor of Biology at Harvard, testifies at public hearing of Cambridge, Mass., City Council, held to consider granting Harvard permission to build a high-security lab where recombinant DNA research would be carried out.

future investigations were promulgated. The now legendary Asilomar Conference in February, 1975, classified experiments according to risk (banning some for the present), set laboratory standards for each category, and indicated appropriate host-vector systems to be used.

Revised and expanded, these recommendations form the basis of the NIH guidelines on recombinant DNA research issued at the end of June. Scientists expect that the guidelines, which apply only to NIH-funded research, will also be accepted by private laboratories here and investigators abroad.

However, the controversy may not be over technical safety so much as ethical considerations, suggested Dr. Curtiss, a view shared by Dr. Roland F. Beers, Jr., of Miles Laboratories.

Coronary Artery Aneurysm: Less Rare Than Suspected?

Medical Tribune Report

PHILADELPHIA—Eleven new cases of coronary artery aneurysms, bringing to 34 the world's known total of this disorder, were reported here by a University of Iowa team.

Suggesting that the condition may be more common than is now suspected, Dr. Herman L. Falsetti said the Iowa series was identified in a population of 742 patients who were referred for cardiac catheterization and coronary arteriography from July, 1973 to April, 1975.

The prospective study showed the clinical picture in patients with coronary aneurysms to be similar to that of severe coronary artery disease, diagnosis being possible only by coronary arteriography, Dr. Falsetti told the American College of Physicians.

The 11 patients in the series, including 10 men and one woman, ranged in age from 35 through 69 and had had symptoms from one month to 14 years. Five patients had had previous myocardial infarctions.

In 10 of the 11 patients, the coronary artery aneurysms were multiple and associated with extensive coronary

atherosclerosis. Left ventricular function was impaired when measured by end-diastolic pressure, end-diastolic volume and ejection fraction, the investigator said. Segmental left ventricular pressure contractions were "severely abnormal."

"There is no significant difference in the distribution of aneurysms between those thought to be atherosclerotic or those due to congenital or other malformations," he observed. "In general those due to trauma or mycotic in nature are often single. Those secondary to inflammatory disease, such as polyarteritis or atherosclerosis, are multiple. To be emphasized, however, is that the presence of one coronary artery aneurysm should lead to the suspicion of others in the heart as well as other parts of the body."

Seven patients in the Iowa series and eight in the published reports underwent surgery, Dr. Falsetti noted. Thirteen were alive in the immediate postoperative period, and of our seven patients all are still alive and have had improvement in their symptoms." Dr. Falsetti is Professor of Medicine at the University of Iowa.

"I GOT LOST— LOST IN MY OWN NEIGHBORHOOD"

Yesterday I was going to the grocery store and suddenly I didn't know the way. I was all mixed up... I thought it was the old neighborhood. It frightened me—and it's not the first time. My children say it's my second childhood. Well it's not. I took care of my kids. Please, doctor.

WHEN "GRAY AREA" SYMPTOMS START TO AFFECT THE ELDERLY PATIENT'S LIFE


A SINGLE 1-mg HYDERGINE SUBLINGUAL TABLET THREE TIMES A DAY.

- Meets the proper 3-mg total daily dose of Hydergine therapy.
- Makes compliance easier for patients who might be confused by more complicated schedules.
- Helps assure optimal dosage because of better adherence to dosage regimen.
- Oval shape of 1-mg tablet makes it easier for the elderly patient to identify.

Contraindications: Hypersensitivity to the drug. **Precautions:** Because the target symptoms are of unknown etiology, careful diagnosis should be attempted before prescribing Hydergine sublingual tablets.

Adverse Reactions: Serious side effects have not been found. Some sublingual irritation, transient nausea, and gastric disturbances have been reported. Hydergine sublingual tablets do not possess the vasoconstrictor properties of natural ergot alkaloids.

Dosage and Administration: 1 mg sublingually three times daily. Alleviation of symptoms is usually gradual and results may not be observed for 3-4 weeks.



GIVE ENOUGH, SOON ENOUGH
LONG ENOUGH

HYDERGINE 1mg Sublingual Tablets

Each 1-mg Hydergine sublingual tablet contains dihydroergocornine 0.333 mg, dihydroergocristine 0.333 mg, and dihydroergokryptine 0.333 mg, as the mesylates, representing a total of 1.0 mg

SANDOZ PHARMACEUTICALS, EAST HANOVER, NEW JERSEY 07936



Scottish & Newcastle
Sellops GB Ltd
Seton Healthcare Group
Sheaffer Pen (UK) Ltd
Smith & Nephew
SmithKline Beecham
Somerville Stores
Sony United Kingdom
St Ivel Ltd
Stratford-Up-Avon
Tate & Lyle Sugars
Taunton Cider plc
Telford Foods Ltd
Tesco Stores Ltd

"packaging
other exhibi
opportunity
to meet. M
not availab
chance to
discussing
new ideas
Kevin Hyde,
Wella Groat

The Boots Com
The Cheese Co
The Invergord
The Korrygord
The New Cov
The Ryvita Co
The Wellcom
Thorntons P
Tomy UK Ltd
Tovall Heal
Trallford Po
Tranfield C
Treats Gro
Trebor Ba
Tulip Inter
Vitameal
W A Turn
W Jordan
Wella Gro
Westler
White A
Whitwo
Wickes
Woolw

Interview Probes Decision to Immunize All

Continued from page 1

other medications, and the usefulness of other available agents, such as antibiotics and amantadine, in curtailing the ravages of an epidemic.

In discussing the reasoning behind the planned utilization of 200 million doses of the monovalent vaccine and 20 million doses of combined swine and Victoria vaccines for high-risk persons, Dr. Cooper told Dr. Sackler that "the entire population is susceptible to infection."

Stockpiling Discarded

And because a flu epidemic "can spread like fire," the HEW Assistant Secretary for Health said the stockpiling option was discarded. Too much time would elapse between a given outbreak and activation of a vaccination program, he stressed.

Asked why, then, the government could not move as quickly in clearing drugs against such other problems as cardiovascular disease and high blood pressure, Dr. Cooper cited "differences between biologicals and other forms of pharmaceuticals."

Dr. Cooper specified, for example, that "the information we have regarding toxicity and effectiveness of other influenza vaccines developed and used in recent years is generally applicable to this vaccine." Furthermore, he said, "the swine flu threat is considered imminent, and there is no other way to prevent the potential morbidity and mortality..." On the other hand, noted Dr. Cooper, cardiovascular drug treatments "are already available covering such drug class and each disease factor. The basis of approval for each type of therapeutic agent must rest on sound scientific principles and substantial evidence of safety and effectiveness... as required by the Food, Drug and Cosmetic Act."

The HEW official conceded that "although prevention is the only way to curb high morbidity and mortality from influenza... antibiotic therapy [is] very important." Antibiotics "will almost certainly be employed," he said, though in some cases this therapy may be "too late" or "insufficient."

Considering the hypothetical pro-

tection against viruses offered by massive doses of ascorbic acid, the availability of amantadine—a drug with antiviral effects, and the unpredictability concerning an epidemic, wouldn't it be as logical, Dr. Sackler asked, to support such measures as to support the program?

"The value of massive doses of vita-



The first injection of experimental swine flu vaccine went into Dr. Harry Meyer, Director of FDA's Bureau of Biologics. Preparing to give the shot is HEW's Assistant Secretary for Health, Dr. Theodore Cooper.

mins still remains to be established [and] expert opinion still does not consider amantadine a replacement for the vaccine," replied Dr. Cooper.

In the next issue: Dr. Cooper discusses the results of clinical trials with the swine-type vaccine, the possible need for a damage compensation mechanism, and the reliance on "past experience" for chronic toxicity data.

Dr. Comfort Urges Caution in Prescribing Drugs for Elderly

Medical Tribune Report

LOS ANGELES—Drugs can and do play a key role in helping the older man or woman cope with the fears, anxieties, depressions and psychoses that accompany advancing age, Dr. Alex Comfort told a meeting of the American Geriatrics Society here. However, the gerontological expert warned, the physician must be sure that the elderly patient's emotional and psychiatric disturbances have not been brought on or exacerbated by overmedication.

"The prescription of any drug, even aspirin, is no light matter," Dr. Comfort said. "Old people go crazy because they were crazy when they were young, because they are ill, or because we drive them crazy. Many older patients are overmedicated with drugs they have bought themselves over the counter or which have been prescribed by doctors. In many cases, old people are just simply zonked out."

Plastic Bag Therapy

When treating an elderly patient, the physician's most important tool may be a plastic bag, Dr. Comfort counseled. "The bag should be given to the patient or to his family to collect all the medications the patient is taking. Sometimes a very large bag is necessary because the patient may be taking as many as 20 or 30 different medications."

Once the patient has been weaned of his vast supply of drugs, a proper assault on the patient's problems may begin. According to Dr. Comfort, successful control of psychiatric and emotional disturbances can be achieved with treatment that includes counseling, occupational and recreational activities—and a well-controlled drug regimen.

Depression, for example, will respond to any of several drugs, including tricyclics, methylphenidate, phenel-

zine, and tranlycypromine, Dr. Comfort said. "Methylphenidate should be used in small amounts or you'll send your patient up the wall. Phenelzine could be used for depressions marked by obsessions and tranlycypromine might be worth trying before ECT."

ECT, Dr. Comfort said, if cautiously but adequately used, could be useful against depressions, especially those marked by suicide threats. "And," Dr. Comfort added, "Don't be afraid to talk to the patient about suicide. You won't cause it... And you may prevent it."

The elderly hypochondriac will also respond to proper treatment. "The last thing the hypochondriac needs," Dr. Comfort cautioned, "is a detailed explanation that his disease is psychosomatic."

Moreover, the hypochondriac should not be subjected to a series of needless surgeries meant to placate or, worse, to punish. "Don't approach with the philosophy that 'if the old bat thinks she has cancer then, by God, let's do a bronchoscopy and show her,'" Dr. Comfort said.

Proper treatment for the hypochondriac includes adequate observation, a prescription for an inert, mildly unpleasant placebo, and a follow-up appointment in two or three weeks.

To treat paranoia adequately, Dr. Comfort said, the physician must learn to distinguish between the real thing and well-founded anger. "Old people," Dr. Comfort said, "do have a tough road in our culture and not every complaint is paranoia."

One hint: "In most cases, the paranoia relates to domestic matters. It's not that the Nazis are out to get him, but that someone is stealing the mail—meaning that they forgot to mail letters or to write—or that people are always throwing dirt into the laundry—mean-

ing that they forgot to turn on the washing machine."

Once paranoia has been adequately diagnosed, Dr. Comfort said, a major tranquilizer, administered in low dosages and in liquid form, may very well alleviate feelings of persecution and discrimination. "But be sure to give the tranquilizer in a liquid form," Dr. Comfort emphasized. "Paranoics have a thing about pills. They think people try to poison them with pills and will usually just hide them behind their dentures and spit them out later."

Ventilating Anxieties

The acute and chronic anxieties that are brought on by moves or other changes in the environment respond well to simple crisis intervention. "Help the patient ventilate his or her anxieties," Dr. Comfort suggested. "Help them relearn the environment."

Because older people worry about changes in their sleeping patterns, they should also be taught that with advancing age, sleep requirements and sleep habits change. "In old age, stage three sleep is short and sleep, generally, is lighter," Dr. Comfort said. "Reassure the patient that the new sleeping patterns, including daytime catnaps, are normal. Milk-based hot drinks are effective in helping the patient sleep."

Sleeplessness brought on by agitated depression, mania, or by acute anxieties, Dr. Comfort added, can be treated for two or three days with tricyclics, a major sedative or a nonbarbiturate hypnotic.

When the patient is burdened by so-called nursing home disease—a disturbance marked by blunting, regression, depression, and pseudodementia—therapy is often effective. Because the syndrome is triggered when the patient loses his job, is abandoned by his family or is treated as incompetent, Dr. Comfort said, it can be alleviated by giving the patient an adequate personal and social environment. "The patient can and does recover if real social responsibilities are imposed," Dr. Com-

fort said. "But the patient should not be oversupported."

Often, Dr. Comfort said, nursing home disease is mistaken for chronic brain syndrome. True chronic brain syndrome can be diagnosed by—among other things—testing the patient's ability to carry out sequential tasks. Chronic brain syndrome, Dr. Comfort said, can be reversed with drugs. But the best treatment, he added, may be the treatment which, given earlier in life, prevents the onset of the syndrome. Effective treatment of hypertension may be one way of preventing the later appearance of the syndrome.

Elderly people, Dr. Comfort summarized, will respond to proper medical approach. But the doctor must avoid the "false assumption" that the aging process inescapably renders men and women nasty, asexual and incompetent.

"We must also avoid iatrogenic disease," Dr. Comfort emphasized. "Drugs should be used fearlessly if indicated. But they should not be prescribed in large numbers and they should be reviewed periodically."



© 1976, Medical Tribune, Inc.

Dr. Cooper Explains Rationale Behind Swine-Type Flu Shots

Continued from page 1

Was the one death at Fort Dix enough to trigger a national vaccination program?

I should like to stress that the judgment to go forward with a national immunization program was not based solely on the finding of one death at Fort Dix. The dominant reason was that a significantly different flu virus had shown up in an influenza outbreak and had been involved in person-to-person transmission of the disease.

Historically, whenever the influenza virus has undergone a major antigenic shift, and caused a limited outbreak, a major epidemic has followed. In this case, the swine virus has not been identified in person-to-person transmission of the disease for many years. Therefore, virtually the entire population is susceptible to infection.

There is developing debate as to whether the government overreacted. How sure are we that we are going to have an influenza epidemic this year?

I believe we had no choice as public officials but to take the action we did to protect the public health, even though we do not know for sure that there will actually be an epidemic of influenza this fall or winter caused by the swine-type virus now designated as A/New Jersey/76. The decision does show that the government can act with dispatch when it needs to protect health.

Didn't the government have the option of preparing the vaccine, stockpiling it and/or using it in high risk groups?

We considered this option early but discarded it; an influenza epidemic can spread like fire. It would take 10 to 13 weeks from the time we had notice of further swine influenza outbreaks to activate an immunization program, motivate the public to participate, and give the shots. Then it would take two or three additional weeks after vaccination for antibodies to build to an appropriate level. I seriously fear that we could never get ahead of an outbreak in this manner. Furthermore, there would be no saving in cost.

You point out that the "government can act with dispatch when it needs to protect health," but there seems to be no dispatch in government actions in relation to a wide range of drugs for the treatment of the largest "epidemic" cause of death in the U.S.—cardiovascular disease, including high blood pressure. How do you explain this?

I would caution you about comparing approval and use of a vaccine against swine flu; and FDA approval of drugs, for example against high blood pressure. These are three points here: First, there are differences between biologicals and other forms of pharmaceuticals, and the requirements for information necessary to certify safety and effectiveness vary.

Second, this is not a new vaccine entirely. Other vaccines have been developed and used against other forms

of influenza for the past 30 years. The only major difference between this one and the others is in the antigenic qualities of the virus itself. It is not as if we were developing a totally new agent here. The information we have regarding toxicity and effectiveness of other influenza vaccines developed and used in recent years is generally applicable to this vaccine against the swine-type virus.

Third, I agree with you that there is also an epidemic of cardiovascular disease to which high blood pressure is contributor. There are also drugs now available in this country which are effective in the control of hypertension, but there is no drug on the market for the practical treatment of influenza, and no specific preparation generally available—yet—for the prevention of the disease caused by the A/New Jersey/76 strain.

Government regulations for new drugs require proof of efficacy and safety even for minor variations in a particular drug class. The government does not approve a drug on the basis of an immunologic or bacteriologic theory or principle, as you indicated for the flu vaccine. Why would you not favor more vigorous action than we have had for almost 10 years in the clearance of new cardiovascular agents?

The fundamental differences between the current vaccine situation and the cardiovascular situation are these:

The swine flu threat is considered to be imminent, and there is no other way to prevent the potential morbidity and mortality except by the proposed measures. With respect to cardiovascular diseases, there are drug treatments already available covering each drug class and each disease factor requiring treatment. The basis of approval for each type of therapeutic agent must rest on sound scientific principles and substantial evidence of safety and effectiveness based upon adequate and well-controlled studies as required by the Food, Drug and Cosmetic Act.

Mere demonstration of a pharmacologic effect of a cardiovascular agent is insufficient to assure that the particu-

lar agent will be safe and effective in humans, although some predictions in this regard can be made in the case of minor molecular modifications of already existing drug entities. Even in these cases, however, adequate pre-clinical and clinical studies are needed to establish that the predictions are correct.

You have said prevention is the only way to curb high morbidity and mortality from influenza. Do we not also have other means such as improved nutritional status and, of outstanding significance, the availability of antibiotics that are effective against secondary bacterial infections which were a major source of mortality in the 1918-19 epidemic?

Although prevention is the only way to curb high morbidity and mortality from influenza, nutritional status and antibiotic therapy are very important. Antibiotics will most certainly be employed. However, certain strains of flu can cause complications quite rapidly. In such cases, especially in patients with cardiovascular and respiratory disease, antibiotic therapy may be too late or insufficient to prevent morbidity and mortality. The best and most established medical practice is to prevent flu in the first place and use antibiotics as needed.

Theoretically, nutritional status could have some overall effect on influenza disease. However, this would seem to be most important in populations where a high percentage of people were in poor nutritional states, such as populations of developing countries. Nutritional status would not be expected to have a major impact in the United States.

You indicated that there are no drugs on the market for the treatment of influenza but there are for cardiovascular disease. This raises two considerations: 1. Pauling has raised the theoretical point that massive doses of ascorbic acid may be of importance in respect to an epidemic of swine flu because of the effect of ascorbic acid, metal ions and oxygen on nucleic acids and pro-

teins which he maintains "leads to inactivation of viruses and contributes to the control of viral diseases by Vitamin C."

2. Other physicians point to the availability of amantadine. Thus, a nutritional supplement may hypothetically afford some measure of protection over a wider range of viral organisms, in contradistinction to the high specificity of a vaccine. In the other instance, there exists the claim for antiviral effectiveness of a drug for treating an existing viral infection. Furthermore, unpredictability as to whether we will have an epidemic at all or what type it will be is widely acknowledged. Wouldn't it be as logical to support the expertise of such scientists as Pauling as to support the expertise of those who advocate the vaccine? There is debate in both areas. Should the government take a partisan position? If such a partisan position cannot be supported by hard data but by expertise, judgment and theoretical considerations, should not similar criteria be applicable in both instances?

In any position the government takes there is usually going to be a difference of opinion. But the data upon which expert opinion is based must be the best possible. The value of vaccines has already been repeatedly demonstrated. The value of massive doses of vitamins still remains to be established. The OTC Cough and Cold Panel and the OTC Vitamin and Mineral Panel did not find high doses of ascorbic acid to be effective in respiratory disease of viral origin.

Amantadine is one agent that represents a new approach to treatment of viral illnesses. There is some evidence that amantadine can help in symptomatic improvement of infections due to influenza A strains but the mechanism of action is as yet undetermined. Expert medical opinion still does not consider amantadine to be a replacement for vaccine. For patients who cannot take the vaccine, amantadine may be an alternative second choice treatment. Thus, the path that the government has chosen to recommend is based on the best available medical evidence.


Continued Next Issue



On March 24, President Ford, flanked by Dr. Jonas Salk (left), Dr. Cooper, and Dr. Albert Sabin (right), announced and approving an entirely new drug.

WHEN ANXIETY INTERFERES

The cardiac patient and anxiety



"The [cardiac] patient is anxious about minor symptoms, about the implications of his diagnosis, and about real or imagined limitations of function."

The worst is over. The cardiac patient is out of the acute stage, out of the hospital, and well on his way to recovery. How quickly he comes back to near normal functioning may depend on his psychological as well as his physical rehabilitation.

Clinical anxiety, for example, may be one reason for prolonged recuperation following cardiac healing. Yet anxiety can sometimes be beneficial in facilitating patient compliance.


The patient who is realistically concerned about resuming his preoperative functioning may

be highly motivated to adhere to his rehabilitation regimen. However, the cardiac patient with excessive or unresolved anxiety may be so fearful of future heart failure that he refrains from your prescribed regimen.

Excessive anxiety can interfere with patient management

When excessive anxiety diminishes your patient's ability to participate fully in his rehabilitation program, your counseling and reassurance

are often sufficient. But when his anxiety is so great that it actually interferes with his ability to listen and respond, you may wish to consider the addition of an adjunctive antianxiety agent to help reduce his excessive anxiety to more manageable levels.



Librium® (chlordiazepoxide HCl) an effective adjunct to your reassurance and counseling

Safety: Librium has a highly favorable benefits-to-risk ratio and a wide margin of safety. Because of its low incidence of side effects, it is regarded as one of the safest antianxiety agents available. And Librium does not adversely affect the cardiovascular system. See complete product information for warnings, precautions and adverse reactions.

Performance: Hundreds of clinical trials, thousands of published papers, and millions of patients constitute the record of performance for Librium.

Concomitant use: Of special significance in treating the cardiac patient already taking multiple agents is the fact that Librium is used concomitantly with most primary medications, such as cardiac glycosides, diuretics and antihypertensives.

*Zohman BL: Geriatrics 28:110-119, Feb 1973

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Relief of anxiety and tension occurring alone or accompanying various disease states.

Contraindications: Patients with known hypersensitivity to the drug.

Warnings: Caution patients about possible combined effects with alcohol and other CNS depressants. As with all CNS-acting drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Though physical and psychological dependence have rarely been reported on recommended doses, use caution in administering to addiction-prone individuals or those who might increase dosage; withdrawal symptoms (including convulsions), following discontinuation of the drug and similar to those seen with barbiturates, have been reported. Use of any drug in pregnancy, lactation, or in women of childbearing age requires that its potential benefits be weighed against its possible hazards.

Precautions: In the elderly and debilitated, and in children over six, limit to smallest effective dosage (initially 10 mg or less per day) to preclude ataxia or oversedation, increasing gradually as needed and tolerated. Not recommended in children under six. Though generally not recommended, if combination therapy with other psychotropics seems indicated, carefully consider individual pharmacologic effects, particularly in use of potentiating drugs such as MAO inhibitors and phenothiazines. Observe usual precautions in presence of impaired renal or hepatic function. Paradoxical reactions (e.g., excitement, stimulation and acute rage) have been reported in psychiatric patients and hyperactive aggressive children. Employ usual precautions in treatment of anxiety states with evidence of impending depression; suicidal tendencies may be present and protective measures necessary. Variable effects on blood coagulation have been reported very rarely in patients receiving the drug and oral anticoagulants; causal relationship has not been established clinically.

Adverse Reactions: Drowsiness, ataxia and confusion may occur, especially in the elderly and debilitated. These are reversible in most instances by proper dosage adjustment, but are also occasionally observed at the lower dosage ranges. In a few instances syncope has been reported. Also encountered are isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, increased and decreased libido—all infrequent and generally controlled with dosage reduction; changes in EEG patterns (low-voltage fast activity) may appear during and after treatment; blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have been reported occasionally, making periodic blood counts and liver function tests advisable during protracted therapy.

Supplied: Librium® Capsules containing 5 mg, 10 mg or 25 mg chlordiazepoxide HCl. Libritabs® Tablets containing 5 mg, 10 mg or 25 mg chlordiazepoxide.

ROCHE Roche Laboratories Division of Hoffmann-La Roche Inc. Nutley, New Jersey 07110

Adjunctive
LIBRIUM® TV
chlordiazepoxide HCl/Roche
5 mg, 10 mg, 25 mg capsules

THE ANXIETY-SPECIFIC

Mark Rayner, Marketing Director
Julian Gerst, Project Manager
John McKee, Project Manager
Vicki Morison, Administration Manager
Isabel Hutchings, Conference Manager
Gladys Benton-Hughes, Conference Manager

Richmond
Surrey TW9 2LS
Tel: 081 332 2422
Fax: 081 332 0939

Hip Joint Healing May Avoid Surgery

Continued from page 3

ics correlated with the patients improved clinical status.

All of the youngsters, the investigator stressed, had received intensive physical therapy as inpatients in a rehabilitation unit, and all were instructed to maintain a vigorous home exercise program after discharge. All were on a regimen of salicylates and indomethacin, in addition to other anti-arthritis drugs.

Illustrated Case

In a typical history, Dr. Bernstein cited the case of a 12-year-old girl with systemic JRA of nine years' duration, who had severe hip joint pain and needed two canes to walk short distances. Radiographs (see page 1) showed narrowing of the hip joint

spaces and subchondral cysts of both acetabulae and femoral heads.

"Three years later she had no pain, was ambulating without assistance and was able to ride a bicycle," he noted. "Radiography demonstrated widening of joint spaces and sharp cortical margins of the acetabulae and femoral heads.

"In view of the children's improvement," he continued, "it seems unlikely that the increase in joint space was due to joint effusion. Rather, some new articular surface appears to have been provided for joints which previously were almost denuded of cartilage."

Dr. Bernstein observed that a variety of recent studies have challenged the concept that damage to cartilage is irreversible. He cited the widening of

the hip joint that has occurred in some adults following successful femoral osteotomy for osteoarthritis of the hip. Further, he said, experimental studies have shown that the major components of joint cartilage can be renewed even in mature animals; and surgically created defects through cartilage into the subchondral bone may be followed by resurfacing of the joint with tissue having the histologic characteristics of cartilage.

Child's Potential Greater

"It appears possible that, because of a child's greater potential for growth and for remodeling of bone," he declared, "the likelihood of joint restoration is greater than in the adult."

The implications for therapy, his paper suggested, is that an aggressive

rehabilitation program, stressing physical activity, combined with an appropriate medical regimen, offers the most promising chance of joint recovery. Dr. Bernstein commented that in the studies of animals with surgical defects, "new cartilage developed while the animals were permitted free movement; and the cartilage developed at a more rapid pace in the weight-bearing than in the nonweight-bearing areas of the joint. It is possible that a similar situation may have occurred in our patients."

In an interview, Dr. Bernstein's collaborator, Dr. Helen Kornreich, Associate Professor of Pediatrics, said the findings suggest that caution should be exercised before radical bone surgery is recommended in patients with JRA. The fact that joint function may be restored in some patients, suggests, she declared, that "we can't always predict the damage is irreversible." Coauthors included Dr. Deborah Forrester.

This depressed T-cell activity is the single most important indicator of a poor prognosis in the disease, he said.

Fewer Infections

Other poor signs, Dr. Frei said, are identification of the leukemic cell itself as a T-cell, the presence of a mediastinal mass, and a very high white cell count at diagnosis.

Intermittent courses of drug treatment lead to fewer infections than continuous dosing, and they give the blood-forming bone marrow and lymphoid tissues a chance to rest and produce a new population of normal cells, Dr. Frei said.

Dr. Frei cautioned that preliminary studies seem to show that the rate of appearance of second tumors later in life is linked to drugs that disrupt the DNA of the leukemic cells most directly, but not to the antimetabolite drugs, such as folic acid antagonists, that interfere with the protein synthesizing mechanisms of the cell.

Acute Lymphocytic Leukemia Termed a 'Curable Disease'

Medical Tribune Report

WORCESTER, MASS.—Calling acute lymphocytic leukemia in children a "curable disease," Dr. Emil Frei, Director of the Sidney Farber Cancer Institute, Brookline, Mass., told a medical symposium here that if the child receives definitive treatment at a major center specializing in childhood leukemia and remains in complete remission with no relapse for five years, there is only roughly one chance in 10 that a relapse will occur in years five to 10. After 10 years disease free, the probability of relapse is almost nil, Dr. Frei added. Treatment continued longer than two years in these cases offers no advantage in avoiding relapse.

89% Disease Free

Speaking at St. Vincent's Hospital to a symposium on leukemia sponsored by the Leukemia Society of America, Inc., Central Massachusetts Chapter (Worcester), and the hospital, Dr. Frei, Professor of Medicine at Harvard Medical School, reported on 39 children treated at the Sidney Farber Cancer Institute who were taken off their drugs after two or three years of treatment. Thirty-five (89%) of the children are today completely free of disease.

Of four children in the original series (85 children), one died during the initial attempt to induce remission and three others died with a later revised diagnosis of undifferentiated leukemia. Dr. Frei stressed that these last three children had a different disease than the surviving children who had classic acute lymphocytic leukemia (ALL). He said that a review of a similar series from another major cancer center treating large numbers of children with acute leukemia corroborated the results at Sidney Farber. Of roughly 106 children in complete remission, only 10% had a relapse after they were put into remission.

Treatment of acute leukemia in children was "a major success story in cancer chemotherapy," Dr. Frei said. In children with classic ALL, he said, nine out of 10 are alive and disease-free at 36 months. Extrapolating from

earlier series, the survival figure will be 80% at five years and will not be significantly lower at 10 years.

Dr. Frei urged the audience to encourage parents bringing children for treatment to think of the disease as a curable one, although he cautioned that he himself is careful never to tell a parent that his child can be cured, only that the disease is curable.

If the parents are not intimately involved in the treatment plan from the beginning, toxic side-effects of the drugs (falling hair, nausea, vomiting) will add unnecessary psychological burdens to the family, Dr. Frei said.

He said that treatment must be thorough, exact, and should be undertaken only at medical centers with the experience and resources to offer the best chance of successful remission.

Dr. Frei's explanation for successful cure in these cases was that acute lymphocytic leukemia in children, as in all diseases, follows the rule that relapse, if it comes at all, will generally come early in the disease.

The proof of this, he said, is that if treatment is administered early, complications from leukemic cells later invading the brain and spinal cord drop from a rate of 50% to 5% or 10%.

"X-ray treatment to the central nervous system should be factored out of treatment, if possible," he said, adding that various encephalopathies, not well understood, have appeared in some children treated with a combination of high-dose methotrexate and x-ray.

Very high doses of methotrexate without x-ray and followed by a "rescue" drug technique (citrovorum factor) are showing good preliminary results, he said.

Noting that a child at diagnosis carries 10¹² leukemic cells in his body, Dr. Frei said it is not possible to eradicate the "one" remaining leukemic cell that may still exist after a successful course of chemotherapy. "This is not just looking for a needle in a haystack," he said, "it is looking for an atom in a haystack."

It is important to know, Dr. Frei added, that the percent of cells in the

tumor load that are killed remains constant whether 10¹² cells are killed with the first dose of drugs, or whether only 10⁶ cells are killed. The same dose of drug is needed.

Because of the kinetics of cell division, as zero leukemic cell population is approached, none of the usual rules seem to hold, Dr. Frei said. Some other defense mechanism must then keep the reduced number of leukemic cells from producing any signs or symptoms of the disease in the child.

He suggested that the immune system probably takes hold and keeps the remaining cells in check, keeping the child in continuous remission and free from any clinical signs of leukemia.

The evidence that an abnormally functioning immune system is somehow involved in leukemia is that if the T lymphocytes of the patient (one of the two major classes of immune lymphocytes) fail to kill leukemic lymphocytes, the prognosis for the patient is poor.

Asbestos Workers Protest Job-Related Deaths



Protesting the reportedly asbestos-related deaths of 11 fellow workers in 18 months, employees of Johns-Manville Corp., Long Beach, Calif., picketed the plant. Workers want clause in contract to cover asbestos-related illness.

Utility Prices: Bellweather of Stock Trends



Utility Prices:
Bellweather of
Stock Trends

By ELIOT JANEWAY
Consulting Economist

Any move in stock prices in which the utilities do not participate is suspect. A unique group, they are the only stocks that combine the characteristics of IBM and government bonds. They were growth stocks before the growth cult came into speculative vogue, and they have always been income stocks. Twenty years ago, every aggressive, professionally-managed portfolio started out with 25% of its assets invested in a cross section of utilities.


The tricky market history of 1976 has been delineated by the utility stocks. During the worst of the bear market, they seemed the least likely candidates for market leadership. Late last year, however, the utilities forged into the forefront as market performers.

The utility stocks ran out of steam last spring. The market realized that the recovery was not building a firm foundation of economic growth free from inflation. Again, the utilities were the bellwether of market performance. Once they stopped going up, the rest of the market started going down.

The realization that utility stocks had become overpriced relative to the cost of inflation prompted many utility stockholders to test the ability of the market to absorb selling. They quickly found that ability lacking, and buying of utilities stopped.

But the investment environment is gradually changing again, this time for the better. It reflects a practical recognition in the money markets that the

In cerebral and peripheral ischemia associated with arterial spasm



In cerebral ischemia:

direct vasodilation of cerebral vessels; virtually no CNS effect; rare incidence of side effects permits long-term use

In peripheral vascular disorders:

relaxes smooth muscles of larger blood vessels by direct effect unrelated to muscle innervation

For additional product information and professional samples, write on your letterhead to

K Professional Service Department
KENWOOD LABORATORIES, INC.
New Rochelle, New York 10801

bond market drop was overdone.

Investors who were alarmed by their inability to unload utility stocks last spring are suddenly eyeing them as attractive buys.

Ask Janeway

My son has an ocean front lot in Florida, and has proposed that I invest \$40,000 in a house to be built on it. Do you consider this a wise investment and/or a tax shelter?

Cincinnati Physician

Your son's ocean front lot will be worth more if held with a view to taking money out of it in the future, than if you put money into it now. New homes are still more advantageous to buy than to build. No resort or second home is a tax shelter.

Send your questions on finances, investments, taxes to Janeway, MEDICAL TRIBUNE, 880 Third Avenue, New York, N.Y. 10022.

Simple Lab Tests Aid Diagnosis of Secondary High BP

Medical Tribune Report

DALLAS—A complete medical history, physical examination and simple laboratory testing can provide the physician with a 90% accurate detection of secondary hypertension, Dr. Norman Kaplan, of the American Heart Association, told a meeting here of the Society of Nuclear Medicine.

If the initial examination and tests suggest secondary hypertension, additional testing may be required, said Dr. Kaplan. If, for example, the patient is suspected of having:

- Chronic renal disease, additional tests may include BUN, creatinine and intravenous pyelogram (IVP). If positive, renal assay or renal biopsy.
- Renovascular disease, tests include IVP and plasma renin. If positive, renal vein renin and an aortogram.
- Coarctation, blood pressure in legs may be taken, followed by aortogram.
- Primary aldosteronism, testing may include plasma potassium, urinary potassium, plasma renin, plasma or urinary aldosterone.
- Cushing's syndrome, testing includes plasma 17-OHCS after 1 mg dexamethasone, and urinary 17-OHCS after 0.5 and 2.0 mg dexamethasone every six hours for two days each.
- Pheochromocytoma, tests may include a spot urine for metanephrine, urinary norepinephrine and epinephrine.

"No patient will need all of these procedures and relatively few will require any of them," Dr. Kaplan said. However, since idiopathic hypertension is incurable, attempts should be made to identify reversible forms.

ILX B12

hematinics
of
choice

By teaspoon or tablet

- Readily assimilated
- Well tolerated
- Economical

Usual Dosage: ELIXIR—1 to 8 teaspoonsful daily or as directed by physician.
TABLETS—1 tablet 3 times a day or as directed by physician.
Supplied: 12 ounce bottles of Elixir; bottles of 100 Tablets

K Kenwood Laboratories, Inc., New Rochelle, New York 10801
developers and suppliers of Cerebral and Kengesin

for
nutritional
and iron
deficiency
anemias


ILX B12TM
Elixir—each ounce represents: Iron and Ammonium Citrate, 18 gr.; Liver Fraction, 1.3 gr.; Thiamine Hydrochloride, 10 mg; Riboflavin, 4 mg; Nicotinamide, 20 mg; Cyanocobalamin (Vit. B12), 20 mcg; Alcohol 8% by volume.
Tablets—each tablet contains: Ferrous Gluconate, 5 gr.; Vitamin C, 80 mg; Cyanocobalamin (Vit. B12), 10 mcg; Liver Fraction, 2 gr.; Thiamine Hydrochloride, 2 mg; Riboflavin, 2 mg; Nicotinamide, 20 mg.

Mark Rayner Managing Director
Julian Gorst Project Director
John McKee Project Manager
Vicki Morrison Administration Manager
Isabel Hutchings Conference Assistant
Barbara Hughes Conference Assistant


et: 081 332 2422
ax: 081 332 0939

Valium® differs from other benzodiazepines (diazepam)


Valium (diazepam) is the one benzodiazepine with three clinically useful pharmacologic properties In the research laboratory, Valium demonstrated that it possessed potent psychotherapeutic, muscle relaxant and anticonvulsant properties. But the crucial question remained: would these three properties prove to be clinically useful? Extensive clinical testing gave the answer. Yes. Of all the available benzodiazepines, Valium — and only Valium — has three valuable pharmacologic properties that have all proven to have definite clinical utility. Clearly, this makes Valium one of the most useful agents in a physician's armamentarium. And, quite likely, one of the most versatile. Today, Valium is indicated in an impressively broad



range of disorders. As a psychotherapeutic agent, for instance, it's useful for the relief of undue psychic tension and anxiety whether seen alone or associated with organic and functional disorders. It's also useful in psychoneurotic conditions evidenced by anxiety with or without secondary depressive symptoms. Because of its skeletal muscle relaxant effect, Valium is a valuable adjunct in relieving skeletal muscle spasm caused by strains, sprains or inflamed skeletal muscles. And its potent anticonvulsant action makes it a preferred drug (given adjunctively I.V.) in status epilepticus. Drowsiness, ataxia and fatigue are possible side effects, but these and more serious adverse reactions are rarely a problem. Of course, as with all CNS-acting agents, patients should be cautioned about driving, operating dangerous machines or the simultaneous ingestion of alcohol while taking Valium (diazepam).




Injectable Valium has distinct anticonvulsant properties. Sample of EEG's in a patient with status epilepticus — before and 15 seconds after Valium 8 mg I.V. Lombroso CT: Neurology 16:629-634, July 1966.




Preliminary studies in both animals and humans have suggested that Valium may also work at the spinal level by enhancing presynaptic inhibition, a mechanism believed to diminish spasm in skeletal muscle.

Only Valium (diazepam) has a pharmacokinetic profile that includes diazepam, active itself, plus other active metabolites



The unique metabolic pathways of Valium (diazepam)

2-mg, 5-mg, 10-mg scored tablets
2-ml Tel-E-Ject® disposable syringes } 5 mg/ml
2-ml ampuls }
10-ml vials }



Because the various benzodiazepines all have different physical-chemical properties, each, naturally, has a different pharmacokinetic "profile." The "profile" of Valium stands out for a number of reasons. First and foremost is the fact that the major metabolites of Valium, which include desmethyldiazepam, 3-hydroxydiazepam and oxazepam, are all pharmacologically active. And, of course, the parent substance — diazepam itself — is also highly active. Then, too, Valium has demonstrated a highly reliable and consistent pattern of absorption, distribution, metabolism and excretion. Such pharmacokinetic predictability is just one more indication of its overall reliability of performance.

Valium® (diazepam) IV

One of a kind.

Please turn page for a summary of product information.

Valium® (diazepam)

2-mg, 5-mg, 10-mg scored tablets
2-ml Tel-E-Ject® disposable syringes
2-ml ampuls } 5mg/ml
10-ml vials }

- the one benzodiazepine with three clinically useful pharmacologic properties
- a range of clinical applications unmatched by any other benzodiazepine
- dosage flexibility no other benzodiazepine can match
- a distinct pharmacokinetic profile that includes diazepam and three active metabolites

Before prescribing, please consult complete product information, a summary of which follows:

Indications: Tension and anxiety states; somatic complaints which are concomitants of emotional factors; psychoneurotic states manifested by tension, anxiety, apprehension, fatigue, depressive symptoms or agitation; symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinations due to acute alcohol withdrawal; adjunctively in: relief of skeletal muscle spasm due to reflex spasm to local pathology; spasticity caused by upper motor neuron disorders; athetosis; stiff-man syndrome. *Oral form* may be used adjunctively in convulsive disorders, but not as sole therapy. *Injectable form* may also be used adjunctively in: status epilepticus; severe recurrent seizures; tetanus; anxiety, tension or acute stress reactions prior to endoscopic and surgical procedures; cardioversion.

Contraindications: Use of injectable in infants and tablets in children under 6 months of age; known hypersensitivity to drug; acute narrow angle glaucoma; may be used in patients with open angle glaucoma who are receiving appropriate therapy.

Warnings: As with most CNS-acting drugs, caution patients against hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving). Advise patients against simultaneous ingestion of alcohol and other CNS depressants. Withdrawal symptoms (similar to those with barbiturates and alcohol) have occurred following abrupt discontinuance (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating). Keep addiction-prone individuals (drug addicts or alcoholics) under careful surveillance because of their predisposition to habituation and dependence. Use of any drug in pregnancy, nursing women or in women of childbearing potential requires that expected benefit be weighed against possible hazard.

ORAL: Not of value in treatment of psychotic patients; should not be employed in lieu of appropriate treatment. When using oral form adjunctively in convulsive disorders, possibility of increase in frequency and/or severity of grand mal seizures may require increase in dosage of standard anticonvulsant medication; abrupt withdrawal in such cases may also be associated with temporary increase in frequency and/or severity of seizures.

INJECTABLE: When used I.V., the following procedures should be undertaken to reduce the possibility of venous thrombosis, phlebitis, local irritation, swelling, and, rarely, vascular impairment. Inject slowly, taking at least one minute for each 5 mg (1 ml) given; do not use small veins, i.e., dorsum of hand or wrist; extreme care should be taken to avoid intra-arterial administration or extravasation. Do not mix or dilute with other solutions or drugs; do not add to I.V. fluids.

Administer with extreme care to elderly or very ill and those with limited pulmonary reserve because of possibility of apnea and/or cardiac arrest; resuscitative facilities should be available. When used with narcotic analgesic, eliminate or reduce narcotic dosage at least 1/3 and administer in small increments. Not recommended for OB use until additional information is available. Should not be administered to patients in shock, coma or in acute alcoholic intoxication with depression of vital signs.

Precautions: If combined with other psychotropics or anticonvulsants, carefully consider individual pharmacologic effects—particularly with known compounds which may potentiate action of Valium (diazepam), such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants. Protective measures indicated in highly anxious patients with accompanying depression who may have suicidal tendencies. Observe usual precautions in impaired hepatic function; avoid accumulation in patients with compromised kidney function. Limit oral dosage to smallest effective amount in elderly and debilitated to preclude ataxia or oversedation (initially 2 to 2 1/2 mg once or twice daily, increasing gradually as needed or tolerated).

INJECTABLE: Laryngospasm and increased cough reflex are possible during peroral endoscopic procedures; use topical anesthetic and have necessary countermeasures available; hypotension or muscular weakness possible, particularly when used with narcotics, barbiturates or alcohol. Use lower doses (2 to 5 mg) for elderly and debilitated; safety

and efficacy in children under 12 not established.

Adverse Reactions: Side effects most commonly reported were drowsiness, fatigue and ataxia. Infrequently encountered were confusion, constipation, depression, diplopia, dysarthria, headache, hypotension, incontinence, jaundice, changes in libido, nausea, changes in salivation, skin rash, slurred speech, tremor, urinary retention, vertigo and blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations, increased muscle spasticity, insomnia, rage, sleep disturbances and stimulation have been reported; should these occur, use of the drug should be discontinued.

Because of isolated reports of neutropenia and jaundice, periodic blood counts and liver function tests are advisable during long-term therapy. Minor changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after Valium (diazepam) therapy and are of no known significance.

INJECTABLE: Venous thrombosis and phlebitis at injection site, hypoactivity, syncope, bradycardia, cardiovascular collapse, nystagmus, urticaria, hiccups, neutropenia.

In peroral endoscopic procedures, coughing, depressed respiration, dyspnea, hyperventilation, laryngospasm and pain in throat or chest have been reported.

Dosage: Individualized for maximum beneficial effect.

ORAL—Adults: Tension, anxiety and psychoneurotic states, 2 to 10 mg b.i.d. to q.i.d.; acute alcohol withdrawal, 10 mg t.i.d. or q.i.d. in first 24 hours, then 5 mg t.i.d. or q.i.d. as needed; adjunctively in skeletal muscle spasm, 2 to 10 mg t.i.d. or q.i.d.; adjunctively in convulsive disorders, 2 to 10 mg b.i.d. to q.i.d. *Geriatric or debilitated patients:* 2 to 2 1/2 mg 1 or 2 times daily initially, increasing as needed and tolerated. (See Precautions.) *Children:* 1 to 2 1/2 mg t.i.d. or q.i.d. initially, increasing as needed and tolerated (not for use under 6 months).

INJECTABLE: Usual initial adult dose is 2 to 20 mg I.M. or I.V., depending on indication and severity. Larger doses may be required in some conditions (tetanus). In acute conditions injection may be repeated within 1 hour, although interval of 3 to 4 hours is usually satisfactory. Lower doses (usually 2 to 5 mg) with slow dosage increase for elderly or debilitated patients and when sedative drugs are added. (See Warnings and Adverse Reactions.)

I.M. use: by deep injection into the muscle.

I.V. use: inject slowly, take at least one minute for each 5 mg (1 ml) given. Do not use small veins, i.e., dorsum of hand or wrist. Use extreme care to avoid intra-arterial administration or extravasation. Do not mix or dilute with other solutions or drugs; do not add to I.V. fluids.

Moderate psychoneurotic reactions, 2 to 5 mg I.M. or I.V., and severe psychoneurotic reactions, 5 to 10 mg I.M. or I.V., repeat in 3 to 4 hours if necessary; acute alcoholic withdrawal, 10 mg I.M. or I.V. initially, then 5 to 10 mg in 3 to 4 hours if necessary; muscle spasm, 5 to 10 mg I.M. or I.V. initially, then 5 to 10 mg in 3 to 4 hours if necessary (tetanus may require larger doses); status epilepticus, severe recurrent convulsive seizures, 5 to 10 mg I.M. or I.V. initially, repeat in 2 to 4 hours if necessary. In endoscopic procedures, titrate I.V. dosage to desired sedative response, generally 10 mg or less but up to 20 mg (if narcotics are omitted) immediately prior to procedure; if I.V. cannot be used, 5 to 10 mg I.M. approximately 30 minutes prior to procedure. As preoperative medication, 10 mg I.M.; in cardioversion, 5 to 15 mg I.V., within 10 to 15 minutes prior to procedure. Once acute symptomatology has been properly controlled with injectable form, patient may be placed on oral form if further treatment is required.

Management of Overdosage: Manifestations include somnolence, confusion, coma and diminished reflexes. Monitor respiration, pulse, blood pressure; employ general supportive measures, I.V. fluids, adequate airway. Immediate gastric lavage indicated for overdosage with tablets. Use levaterenol or metaraminol for hypotension, caffeine and sodium benzoate for CNS-depressive effects. Dialysis is of limited value.

Supplied: Tablets, 2 mg, 5 mg and 10 mg—bottles of 100 and 500; Tel-E-Dose® (unit dose) packages of 100, available in trays of 4 reverse-numbered boxes of 25, and in boxes containing 10 strips of 10; Prescription Paks of 50, available singly and in trays of 10. Ampuls, 2 ml, boxes of 10; Vials, 10 ml; boxes of 1; Tel-E-Ject® (disposable syringes), 2 ml, boxes of 10. Each ml contains 5 mg diazepam, compounded with 40% propylene glycol, 10% ethyl alcohol, 5% sodium benzoate and benzoic acid as buffers, and 1.5% benzyl alcohol as preservative.



Roche Laboratories
Division of Hoffmann-La Roche Inc.
Nutley, New Jersey 07110

Wednesday, August 4, 1976

MEDICAL TRIBUNE

31

Clinical Trials



TRIBUNE SPORTS REPORT

Steam Bath After Exercise Ups Cardiogenic Shock Risk

Medical Tribune Report
FORT COLLINS, COLO.—Steam baths combined with strenuous exercise may cause cardiogenic shock, particularly in middle-aged persons, and physicians should issue appropriate warnings to their patients, two sports medicine experts advise.

The level of risk depends on physical condition as well as how long and vigorously they exercise prior to or after the steam bath and the duration of exposure to the steam, Dr. Robert H. Pike, a former U.S. Olympic Team physician, told MEDICAL TRIBUNE. He called the dehydrating, oxygen-depriving atmosphere of steam baths a "non-physiological situation."

At Colorado State University here recently, two middle-aged men suffered myocardial infarctions after combining strenuous exercise and steam baths without a rest interval, Elliot Plesse, Ph.D., Associate Professor of Physical

Education, reported. One man had a history of cardiac disease and had complained of chest pains the previous night, Dr. Plesse, who works with Dr. Pike, said in an interview. The victim had a "sweat box" session at the gym just before starting a handball game. "Instead of cooling off first," Dr. Plesse explained, "the fellow went right into more strenuous activity, became even hotter, and suffered cardiogenic shock." Had this person played handball before going into the sweat box,

the result would have been just as disastrous, he emphasized.

Steam baths as well as rubber gym garments are frequently resorted to by college wrestlers to make weight, Dr. Plesse added. "But the body has no way of cooling itself with rubber garments," he said, adding that "using the steam bath does not assist youngsters in maintaining weight loss over a period of time."

Both men urge posting of warnings on steam bath doors.

IMMATERIA MEDICA

Synergetic Bucky Fuller

If you have 25 bucks, you can have a real vacation by taking a look at the way one of the most innovative minds of our time flies. We refer to R. Buckminster Fuller's \$25 book, *Synergetics: Explorations in the Geometry of Thinking*, which Macmillan published and which is no one-night stand.

Largely self-taught, eccentric in his approach, and devastating to the conventional, he is the inventor of the Geodesic Dome, that marvel of stress lines which somehow becomes a sensible, highly useful home, the Dymaxion house, the Dymaxion car (which Detroit ought to reconsider because of its energy concepts), and much more. He has confounded mathematicians, industrialists, engineers and educators.

He has been so busy that so far as we know he never got around to straightening out medicine. He works on a larger scale. As he puts it, "We are going to have to find effective ways for all of humanity to see total Earth."

While a good many intelligent scientists faint dead away at his faith in technology, most of them are fascinated by his viewpoint of nature. He describes our vast industrial complex as "only of kindergarten magnitude compared to the complexity of the biological success of our planet Earth. In its complexities of design integrity, the Universe is technology . . . Man does not spontaneously recognize technology other than his own, so he speaks of the rest as something he ignorantly calls nature."

Or, as they call it in our cell-block, DNA.

While many have characterized "Bucky" as a genius, it's an appella-

tion he declines. "I am not a genius, but I am a terrific package of experience," he says, but no one who has experienced his lectures or his books believes that. He is a genius.

So much so that in 1973 Hugh Kenner wrote a book titled *Bucky, A Guided Tour of Buckminster Fuller* (Morrow). A delightful introduction to this refreshing man, it is an almost necessary bit of equipment for coping with *Synergetics*.


As Fuller describes it, "Synergy means behavior of whole systems unpredicted by the behavior of their parts taken separately." Although he calls it energetic geometry and experientially founded mathematics, some say this description could be applied to medicine.

A Columbia mathematics professor, after hearing Bucky lecture, said: "My only regret is that Euclid and Pythagoras could not have been here."

Bucky sums up the moral of his "experience"—he was 81 years old this past July 12—as: "Dare to be naive."

Have a good time.

Clinical Cliché



Patient had tubular breath sounds.

Enlish & Newcastle Brown
Schlotepe GB Ltd
Seton Healthcare Group PLC
Sheaffer Pen (UK) Ltd
Smith & Nephew
SmithKline Beecham
Somerville Stores
Sony United Kingdom Ltd
St Ivel Ltd
Stratford-Upon-Avon Foods
Tate & Lyle Sugars Purch
Telford Cider plc
Telford Foods Ltd
Tesco Stores Ltd

"packaging focus"
other exhibitions
opportunity it af
to meet. Mixing
not available at
chance to spend
discussing cur
new ideas is se
Kevin Hyde, Packag
Wolla Great Britain

The Boots Company
The Cheese Company
The Gifford Group
The Kerygold Co Ltd
The New Covent Gar
The Ryvite Company
The Wellcome Found
Thornton's PLC
Thornton's plc
Tomy UK Ltd
Tovall Health Drink
Trafford Park Baks
Trenfield of Yorks
Treats Group Ltd
Tulip International
Vitamele Packag
W A Turner Ltd
W Jordan (Cereals)
Wells Great Brit
Westler Foods Ltd
Whitworths Ltd
Whitworths Ltd
Wickes Building
Woolworths plc